CURRICULUM VITAE

DICHIARA:

NOME E COGNOME	Francesco Cognetti
LUOGO E DATA DI NASCITA	Catanzaro 22 aprile 1951
INDIRIZZO	Via F. Denza 19/a 00197 Roma
STATO CIVILE	Coniugato con una figlia.
NAZIONALITA'	Italiana
C.F.	CGNFNC51D22C352B
TELEFONO	06-52665330 /6919
FAX	06-52665637
MOBILE :	335-6571385 348-5294240
E-mail	f.cognetti1@gmail.com francesco.cognetti@ifo.gov.it
Sito web	http://francescocognetti.wordpress.com

TITOLI DI STUDIO

30 ottobre 1975	Laurea in Medicina e Chirurgia – "Università La Sapienza", Roma.
16 marzo 1981	Specializzazione in Medicina Interna.
18 luglio 1984	Specializzazione in Oncologia.
3 settembre 1989	European Certification on Medical Oncology, London

CARRIERA

1/6/'79 - 31/1/'88	Assistente della Divisione di Oncologia Medica I dell'Istituto Regina Elena per lo Studio e la Cura dei Tumori (Roma).
1/2/'88 - 15/2/'91	Aiuto della Divisione di Oncologia Medica I dell'Istituto Regina Elena per lo Studio e la Cura dei Tumori (Roma).
16/2/'91 - 11/12/'94	Primario del Servizio di Oncologia Medica dell'Istituto Regina Elena per lo Studio e la Cura dei Tumori (Roma).
12/12/'94 - 31/12/'95	Primario "ad interim" della Divisione di Oncologia Medica I dell'Istituto Regina Elena per lo Studio e la Cura dei Tumori (Roma).
1/3/'01 – 8/7/'01	Direttore del Dipartimento Oncologia Medica dell'Istituto Regina Elena.
8/7/01 – 18/12/06	Direttore Scientifico * dell'Istituto Regina Elena di Roma per lo Studio e la Cura dei Tumori.
27/2/09 – 31/05/15	Direttore del Dipartimento Oncologia Medica dell'Istituto Regina Elena.
2013 – 2019	Abilitazione Scientifica Nazionale, Professore Ordinario di Prima Fascia, Settore Malattie del Sangue, Oncologia e Reumatologia.
1/01/'96 - Cont.	# Primario di ruolo della Divisione di Oncologia Medica I dell'Istituto Regina Elena per lo Studio e la Cura dei Tumori (Roma).
1/03/2019 – Cont.	Professore Straordinario a tempo determinato presso il Dipartimento di Medicina Clinica e Molecolare dell'Università La Sapienza di Roma

DESCRIZIONE DELL'ATTIVITA' CLINICO ASSISTENZIALE E SCIENTIFICA DELLA DIVISIONE DI ONCOLOGIA MEDICA "1" (IRE) – DIRETTORE PROF. FRANCESCO COGNETTI. VOLUMI DI ATTIVITA' CLINICO ASSISTENZIALE UOC OM1 (MEDIA APPROSSIMATIVA PER ANNO)

	TOTALE	**MEDIA MENSILE**	**MEDIA GIORNALIERA**
VISITE AMBULATORIALI			
Nuovi pazienti	2.500	208	9
Controlli	35.500	2.958	129
Totali	38.000	3.170	138
TRATTAMENTI			
Ambulatoriali + Day Hospital + Degenza	20.508	1.709	75
RICOVERI			
Ordinari	900	75	4
Day Hospital	100	9	/

ATTIVITA' DI SPERIMENTAZIONE CLINICA COMPLESSIVA DELLA DIVISIONE DI ONCOLOGIA MEDICA "1" IRE (DIRETTORE PROF. FRANCESCO COGNETTI)

***Studi Clinici della Divisione di Oncologia Medica I (Direttore Prof. Francesco Cognetti) approvati dal Comitato Etico dal 2010 al 2017.**

Fase di Studio	**Numero**	
Fase I	2	164
Fase II	54	
Fase III	108	
Fase IV e/o Osservazionali	78	
Totale	242	

Patologia	**Numero**
Totale	242
Principal Investigator (F.Cognetti)	**91**
Colon	8
Endometrio	2
HCC	3
Gastrico	1
GBM	3
GIST	1
Mammella	63
Melanoma	33
Mesotelioma	3
Neuroendocrino	4
Osteosarcoma	3
Ovaio	19
Pancreas	13
Polmone	41
Prostata	10
Rene	12
Sarcomi	7
Testa - collo	1
Vescica	2
Vie Biliari	1
Miscellanea	12

***Studi Clinici in corso al 15.11.2018 (CON ARRUOLAMENTO APERTO)**

Fase di Studio	**Numero**		
Fase I	**0 (OM1)**	**1(OM2)-1(DERMATOLOGIA)**	
Fase II	**8**		
Fase III	**24**		
Fase IV e Osservazionali	**17**		
TOTALE	**49**		

Patologia	**Numero**
Totale studi	**49**
Principal Investigator(F.Cognetti)	**18**
Colon	3
Mammella	21

Melanoma	5
Mesotelioma	1
Neuroendocrino	0
Osteosarcoma	1
Ovaio	3
Pancreas	2
Polmone	6
Prostata	2
Rene	2
Sarcomi	2
Testa-collo	0
Vescica	1
Miscellanea	0

*Studi Clinici condotti nel Biennio 2016-2017

Anno	**Numero**
2016	62
Principal Investigator (F.Cognetti)	**11**
2017	73
Principal Investigator (F.Cognetti)	**15**

*Studi Clinici in corso al 22.11.2018

Fase di Studio	**Numero**		
Fase I	0		
Fase II	8		
Fase III	48		
Fase IV e Osservazionali	25		
TOTALE	**95**		

Patologia	**Numero**
Totale studi	**95**
Principal Investigator(F.Cognetti)	**40**
Colon	6
Mammella	34
Melanoma	8
Mesotelioma	2
Neuroendocrino	1
Osteosarcoma	1
Ovaio	8
Pancreas	5
Polmone	13
Prostata	6
Rene	2
Sarcomi	3
Testa-collo	1
Vescica	1
Miscellanea	4

*Proposte di nuovi Studi Clinici in varie fasi di attivazione

Fase di Studio	**Numero**
Fase I	1
Fase II	4
Fase III	15

Fase IV e Osservazionali	0
Totale	**20**

Patologia	**Numero**
Totale	**20**
Principal Investigator (F.Cognetti)	**10**
Colon	1
Gastrico	1
GIST	0
Glioblastoma	0
HCC	1
Mammella	4
Melanoma	2
Mesotelioma	0
Neuroendocrino	0
Osteosarcoma	2
Ovaio	3
Polmone	5
Prostata	0
Rene	0
Testa-collo	1
Urotelio/vescica	0
Miscellanea	0

***PRINCIPALI RISULTATI CONSEGUITI DURANTE L'ATTIVITA' DI DIREZIONE SCIENTIFICA DELL'ISTITUTO NAZIONALE TUMORI REGINA ELENA (IRE) DI ROMA (08-07-2001/18-12-2006)**

ATTIVITA' SCIENTIFICA IRE

ANNO	N° PUBBLICAZIONI	%	IF NORMALIZZATO	%
2001	128		431	
2007	249	+ 94%	1052	+ 144%

ARRUOLAMENTO PAZIENTI IN STUDI CLINICI

ANNO	N° PAZIENTI	%
2001	**500**	
2006	**4591**	+ 818%

EVENTI FORMATIVI, CONGRESSI SCIENTIFICI ED ECM

ANNO	NUMERO EVENTI/CONGRESSI	NUMERO ECM	%
2001	41	0	
2006	152	931	+ 271%

FINANZIAMENTI PER LA RICERCA

ANNO	PUBBLICI	%	PRIVATI	TOTALE
2000	€ 2.641.000		???	
2006	€ 5.422.000	105%	€ 1.898.537	€7.320.000

SOCIETA' SCIENTIFICHE

1976 - Cont. Membro dell'Associazione Italiana di Oncologia Medica (AIOM).

1985 - Cont. Membro dell'American Society of Clinical Oncology (ASCO).

1989 - Cont. Membro della European Society of Medical Oncology (ESMO).

1990 - 2004 Membro del Consiglio Direttivo Nazionale dell'Associazione Italiana di Oncologia Medica (AIOM).

1991 - 1997 Chairman del Membership Committee della European Society for Medical Oncology (ESMO).

1991 - 2001 Membro dell'Executive Committee Board della European Society for Medical Oncology (ESMO).

1993 - 1996 Membro del Consiglio Direttivo Nazionale della Società Italiana di Endocrinologia ed Immunologia Oncologica.

1994 - 2003 Chairman della Commissione Educazionale dell'Associazione Italiana di Oncologia Medica (AIOM).

1995 - 1997 Membro del Council of the Federation of the European Cancer Societies (FECS).

1995 - 2000 Tesoriere Nazionale dell'Associazione Italiana di Oncologia Medica (AIOM).

1996 Membro del Comitato Scientifico del "21st ESMO Congress" Vienna, Austria November 1-5, 1996.

1997 - 2003 Membro del Membership Committee della Federation of the European Cancer Societies (FECS).

1997 - 1999 Membro del Comitato Guida della Sperimentazione MDB.

1998 - 1999 Coordinatore della fase osservazionale della Sperimentazione MDB per la Regione Lazio.

1998 Presidente del "1° Congresso Nazionale dell'Associazione Italiana di Oncologia Medica (AIOM)".

1998 - 1999 Membro del Comitato Scientifico del "1° Congresso Nazionale dell'Associazione Italiana di Oncologia Medica (AIOM)", Roma 24-28 ottobre 1999.

1999 - 2000 Membro del Comitato Scientifico del "2° Congresso Nazionale dell'Associazione Italiana di Oncologia Medica (AIOM)", Genova 28-31 ottobre 2000.

1999 - 2000 Presidente Eletto dell'Associazione Italiana di Oncologia Medica (AIOM).

1999 - 2001 Presidente del Comitato Scientifico del "3° Congresso Nazionale dell'Associazione Italiana di Oncologia Medica (AIOM)", Napoli 4-7 novembre 2001.

2001 - 2005 National Representative for Italy of European Society for Medical Oncology (ESMO).

2001 - 2004 Membro dello Steering Committee of National Representative for Italy of European Society for Medical Oncology (ESMO).

2001 – 2003 Membro del Nominating Committee of European Society for Medical Oncology (ESMO).

2001 - 2003 Presidente Associazione Italiana Oncologia Medica (AIOM).

2003 - 2008 Presidente della Fondazione per la Ricerca Oncologica FO.R.O. ONLUS.

2003 - 2008 Socio Fondatore e Sindaco Effettivo del Collegio Sindacale di "Galileo 2001 – Associazione per la libertà e la dignità della scienza".

2005 - 2006 Presidente della Fondazione AIOM (Associazione Italiana di Oncologia Medica).

2005 - 2009 Membro Comitato Scientifico Ansa Progetto Sanità Italia.

2005 - Cont. Membro Consiglio Direttivo Fondazione AIOM (Associazione Italiana di Oncologia Medica).

2007 – Cont. Membro del Comitato Scientifico della Fondazione Roma Chirurgia.

2010 – 2011 Media Ambassador per l'European Society for Medical Oncology (ESMO).

2010 – Cont. Membro Comitato Scientifico Fondazione "I Sud del Mondo – ONLUS".

2011 – Cont. Membro Comitato Scientifico EURISPES.

2012 – Cont. Media Ambassador per l'European Society for Medical Oncology (ESMO).

2013 – Cont. Presidente Fondazione "Insieme contro il Cancro" .

2015-Cont. Membro Emerito di ASCO (American Society of Clinical Oncology)

INCARICHI IN ORGANISMI DI RICERCA

1982 - 1997 Membro attivo del'Head and Neck Cancer Cooperative Group of EORTC (European Organization for Research and Treatment of Cancer).

1982 - 1998 Membro dell'Head and Neck Cooperative Group dell'EORTC.

1985 - 1997 Membro del Subcommittee on Chemotherapy of the EORTC Head and Neck Cooperative Group.

1989 - 1993 Segretario del Head and Neck Cancer Cooperative Group of EORTC.

1993 - 2000 Membro del Comitato Consultivo del Centro di elaborazione dati clinici del Mezzogiorno del CNR, nell'ambito del Progetto Finalizzato "Applicazioni cliniche della ricerca oncologica".

1993 - 2001 Responsabile del Coordinamento scientifico ed organizzativo per il Centro-Sud del Progetto ALPI (Adjuvant Lung Project Italy) nell'ambito del Progetto Finalizzato CNR "Applicazioni cliniche della ricerca oncologica".

1994 - 1997 Membro of the EORTC Study Group on Continuing Medical Education (CME).

2001 Presidente Consiglio Scientifico presso Scuola Superiore di Oncologia.

2001 - 2010 Componente Ex-Officio Comitato Etico Istituti Fisioterapici Ospitalieri.

2002 - 2009 Membro del Comitato Scientifico del Centro Nazionale di Adroterapia Oncologica CNAO.

2002 - Cont. Membro Consiglio Direttivo Consorzio Oncotech – Università degli Studi di Napoli.

2003 – 2008 Membro del Comitato Operativo Italia - USA per la ricerca in campo oncologico.

2003 – Cont. Coordinatore gruppo GIM (Gruppo Italiano Mammella).

2007 – Cont. Coordinatore gruppo GIR (Gruppo Italiano Rene).

2015- Cont. Membro dello Steering Committee PERIPLO (Gruppo di Lavoro interregionale su percorsi diagnostico-terapeutici, eccellenza, innovazione e responsabilità di cura).

PREMI

29.05.2010 Premio Internazionale Sebetia-Ter per le Scienze Biomediche (Università di Napoli "Federico II").

INCARICHI DI COORDINAMENTO DI PROGETTI DI RICERCA E/O STUDI CLINICI

1982 - Cont. Responsabile di studi clinici sul trattamento antiemetico in corso di chemioterapia antineoplastica.

1984 - 1990 Ricercatore responsabile del progetto: "Studio dell'applicazione della chemioterapia come trattamento iniziale induttivo alle terapie loco-regionali del carcinoma squamoso della testa e collo in fase avanzata", finanziato nell'ambito del Progetto Finalizzato Oncologia del CNR.

1988 - 1990 Responsabile di un progetto di studio europeo EORTC sul trattamento del carcinoma indifferenziato del rinofaringe.

1990 - 1995 Responsabile di un progetto di studio dell'Istituto Regina Elena sul carcinoma localmente avanzato della mammella.

1991 - 1995 Ricercatore responsabile del progetto di ricerca "Presupposti biologici per la corretta integrazione di terapie nei tumori della testa e collo", finanziato dall'Associazione Italiana per la Ricerca sul Cancro (AIRC).

1991 - 1995 Ricercatore responsabile del progetto di studio "Studio randomizzato di fase III chirurgia più chemio-radioterapia in pazienti con carcinoma squamoso della testa e collo localmente avanzato operabile", finanziato nell'ambito del progetto "Le applicazioni cliniche della ricerca oncologica" del CNR.

1993 - 1996 Coordinatore del progetto EORTC "A randomized phase III study on post operative radio and chemotherapy in patients with locally advanced head and neck carcinoma" (Protocollo n. 22931).

1993 - 1996 Coordinatore del Progetto EORTC "A phase III randomized study on the role of booster dose of post operative radiotherapy in patients with early stage carcinoma of the head and neck" (Protocollo n. 22932).

1994 - 1998 Responsabile del progetto di ricerca "Indicatori di prognosi e risposta terapeutica nel trattamento primario ad alte dosi del carcinoma mammario localmente avanzato nell'ambito del Progetto ACRO del CNR".

1994 - 1996 Responsabile del progetto di ricerca AIRC "Intensificazione della dose di chemioterapia nel trattamento del carcinoma mammario avanzato e analisi del significato prognostico di alcuni fattori biologici".

1998 Coordinatore dello "Studio di fase II con Multiterapia Di Bella (MDB) in pazienti affette da carcinoma mammario metastatico non suscettibile di trattamento ormono o chemioterapico".

1998 Coordinatore dello "Studio di fase II con Multiterapia Di Bella (MDB) in pazienti affetti da carcinoma squamoso del distretto cervico-facciale e dell'esofago metastatico recidivo dopo una prima linea chemioterapica".

1998 - Cont. Coordinatore dello "Studio randomizzato cooperativo nazionale di fase III di chemioterapia adiuvante in pazienti con carcinoma mammario operato e ad alto rischio di recidiva (N >3)".

1998 – Cont. Membro Comitato Scientifico Studio TAXIT 216.

1998-2005 Chairman Studio Sequential epirubicin-docetaxel-cmf as adjuvant therapy for node-positive early stage breast cancer: updated results of the taxit216 randomized trial.

1999 - 2005 Coordinatore per l'Italia dello "Studio randomizzato di fase II Herceptin (anti-Erb 2) plus taxotere vs taxotere alone in metastatic breast cancer patients Erb 2 positive".

2000 - Cont. Coordinatore dello "Studio cooperativo nazionale di chemioterapia adiuvante vs controllo in pazienti con carcinoma della vescica sottoposti ad intervento radicale".

2001 - 2003 Coordinatore del Progetto Finalizzato Lega Italiana per la Lotta contro i Tumori "Validazione di strategie di diagnosi clinica e molecolare per la valutazione del rischio per la diagnosi e per la prevenzione del tumore mammario ad incidenza familiare".

2001 – 2010 Coordinatore studio nazionale di chemioterapia adiuvante nel carcinoma uroteliale della vescica sottoposto a cistectomia radicale.

2002 - 2004 Coordinatore del Progetto Finalizzato Ministero della Salute "Programma di sorveglianza per la identificazione e prevenzione dei tumori mammari in soggetti ad alto rischio genetico".

2002 - 2003 Coordinatore del Progetto Finalizzato CNR-MIUR "Monitoraggio biochimico del marker di attività angiogenica VEGF: Implicazioni prognostiche e terapeutiche nel melanoma cutaneo".

2002 - 2003 Coordinatore del progetto CNR-MIUR "Monitoraggio biochimico del marker di attività angiogenica VEGF: Implicazioni prognostiche e terapeutiche nel melanoma cutaneo".

2002 Coordinatore del progetto finalizzato Ministero della Salute / Regione Calabria "Uso di tecnologie innovative per l'identificazione di bersagli molecolari nelle patologie neoplastiche sporadiche ed ereditarie".

2003 - 2005 Coordinatore del Progetto Istituto Superiore di Sanità "Il valore predittivo del test "estreme drug resistance" in pazienti con carcinoma ovarico refrattario sottoposti a chemioterapia test-selezionata confrontata con chemioterapia non-test selezionata".

2003 – Cont. Membro Comitato Scientifico Studio GIM 1 e 2.

2003 – Cont. Chairman Studio GIM1-N. Studio clinico randomizzato di fase III di terapia sequenziale con Epidoxorubicina e Ciclofosfamide (EC) seguito da Docetaxel (EC?D) versus la combinazione di 5-Fluorouracile, Epidoxorubicina, Ciclofosfamide (FEC) come trattamento adiuvante nelle pazienti con carcinoma della mammella con linfonodi negativi.

2003 – Cont. Chairman Studio GIM2. Studio randomizzato di fase III con EC seguito da Paclitaxel verso FEC seguito da Paclitaxel, somministrati ogni 2 o 3 settimane

supportato da Pegfilgrastim, per pazienti con carcinoma mammario operato (4 BR).

2004 - 2005 Coordinatore del Progetto Istituto Superiore di Sanità "Le basi metodologiche per una chemioterapia anti-tumorale mirata: il saggio dell'EDR nel carcinoma ovarico ed in altre neoplasie".

2004 - 2005 Coordinatore del progetto Istituto Superiore di Sanità contributo clinico-scientifico allo studio del carcinoma della mammella, del colon, dell'ovaio e del polmone (programma Italia - USA "Farmacogenomica Oncologica - Oncoproteomica") - Italia-Usa 1° anno.

2004 - 2006 Coordinatore del progetto Regione Calabria "Sperimentazione di una rete oncologica della Calabria e l'Istituto Nazionale dei Tumori".

2004 - 2006 Coordinatore del Progetto Istituto Superiore di Sanità "Contributo clinico-scientifico allo studio del carcinoma della mammella, del colon, dell'ovaio e del polmone" (programma Italia-USA "Farmacogenomica Oncologica – Oncoproteomica").

2004-2007 Coordinatore dello "Studio con BAY 43-9006 in pazienti con cancro del rene non recabile e/o metastatico".

2004-2008 Coordinatore dello "Studio con AG-013736 ± Docetaxel in pazienti con carcinoma mammario metastatico".

2005 Coordinatore del progetto Ministero della Salute "Farmacogenetica ed endocrino terapia nel carcinoma mammario. Impatto di varianti polimorfiche dei geni CYP2D6 e CYP19 sull'efficacia e la tossicità delle terapie ormonali nel carcinoma mammario".

2005 - 2006 Coordinatore del progetto Istituto Superiore di Sanità "Programma Italia - USA "Farmacogenomica Oncologica - Sieroproteomica" (Borse di Studio).

2005 - 2006 Coordinatore del progetto Istituto Superiore di Sanità (*rinnovo*) Contributo clinico - scientifico allo studio del carcinoma della mammella, del colon, dell'ovaio e del polmone (programma Italia - USA "Farmacogenomica Oncologica - Oncoproteomica") – Italia - Usa 2° anno.

2005-2008 Coordinatore dello "Studio con SKI-606 in pazienti con cancro della mammella in fase avanzata metastatica".

2005-2009 Coordinatore dello "Studio di fase II con Arimidex in combinazione con Iressa in donne in post-menopausa con cancro della mammella metastatico".

2005-2009 Coordinatore dello "Studio in pazienti con cancro del colon-retto metastatico trattati in prima linea con Folfox ± PTK 787".

2005 - Cont. Coordinatore del Progetto Ministero della Salute "Meccanismi molecolari implicati nella generazione di resistenza al trattamento con Herceptin in carcinomi della mammella".

2006 - Cont. Coordinatore del progetto Ministero della Salute "Studio randomizzato di fase III di chemioterapia preoperatoria verso postoperatoria con cisplatino e gemcitabina nel carcinoma del polmone non a piccole cellule".

2007-Cont. Coordinatore dello "Studio con Ixabepilone + Trastuzumab vs Docetaxel + Trastuzumab in pazienti con tumore della mammella Her2+ localmente avanzato e/o metastatico".

2008 – Cont. Coordinatore dello "Studio con MAC-321 somministrato per via intravenosa in pazienti con cancro metastatico della mammella resistente ai taxani".

2008 – Cont. Coordinatore dello "Studio con Neratinib vs Lapatinib in associazione Capecitabine in pazienti con cancro della mammella ErbB-2- positivo localmente avanzato o metastatico".

2008-Cont. Coordinatore dello "Studio con Carboplatino e Paclitaxel ± ZD4054 in pazienti con carcinoma ovario avanzato sensibile alla chemioterapia a base di Platino".

2008-Cont. Coordinatore dello "Studio EDRA di confronto tra chemioterapia standard e chemioterapia Estreme Drug- Resistance-Test selezionata dopo chirurgia citoriduttiva di prima istanza nel carcinoma ovario avanzato".

2008-Cont. Coordinatore dello "Studio MOTOR con Torisel come trattamento di II linea in pazienti con carcinoma renale avanzato".

2008-Cont. Coordinatore dello "Studio di radioterapia seguita da Temozolomide in pazienti con melanoma metastatico a livello cerebrale".

2012- 2014 Coordinatore studio di Fase III, randomizzato, doppio cieco, placebo vs AMG + paclitaxel e carboplatino, prima linea carcinoma ovarico, peritoneale primario o delle tube di Falloppio stadio FIGO III-IV

2012- 2014 Principal Investigator Studio di Fase III prospettico, a due coorti, non randomizzato, per valutare la sicurezza di trastuzumab s.c. in somministrazione assistita e auto-somministrazione adiuvante

2012- 2014 Principal Investigator Studio in aperto con everolimus + exemestane in donne in post-menopausa con carcinoma mammario ER+ localmente avanzato o metastatico progredite dopo terapia endocrina

2012- 2014 Principal Investigator Studio fase III, doppio cieco, di confrontro tra dabrafenib + trametinib vs dabrafenib + placebo in prima linea in melanoma stadio IIIC-IV, BRAF V600E mutato

2012- 2014 Principal Investigator Studio BEACON, fase III, randomizzato, NKTR-102 vs trattamento di scelta del medico in carcinoma della mammella avanzato pretrattate con antracicline/taxani/capecitabina

2012- cont. Principal Investigator Studio fase III, randoomizzato in prima linea, pazienti anziani NSCLC: chemioterapiapersonalizzata vs standard

2013- cont. Principal Investigator Studio fase III, randomizzato, di mantenimento con olaparib dopo prima linea a base di platino in carcinoma ovarico FIGO III-IV e BRCA mutato

2013- cont. Principal Investigator Studio fase III, randomizzato, di mantenimento con olaparib vs placebo, in carcinoma ovarico BRCA mutato, platino sensibile, con risposta completa o parziale dopo terapia con platino

2013- cont. Principal Investigator Studio fase I-II: Nab-Paclitaxel + Ldox in pazienti carcinoma della mammella avanzato HER negativo

2014-2016 Chairman Studio di fase I-II di trattamento settimanale di Nab-Paclitaxel (nanoparticlealbumin-bound-paclitaxel) in combinazione con Doxorubicina Liposomiale (LDox) in pazienti con tumore della mammella in fase avanzata HER negativo (ABRAMYO).

2014- 2014 Principal Investigator Studio di Neratinib + Capecitabina vs Lapatinib + Capecitabinain pz con carcinoma mammario metastatico HER-2+, dopo almeno 2 linee precedenti con anti-HER-2

2014- 2015 Principal Investigator Studio fase III, randomizzato: olaparib vs cehmioterapia standard scelta dal medico, in pazienti con carcinoma della mammella metastatico BRCA 1/2 mutate

2014 -2014 Principal Investigator Studio fase III randomizzato sul trattamento neoadiuvante nel carcinoma della mammella in pz HER2+: trastuzumab emtansine + pertuzumab vs chemioterapia + trastuzumab + pertuzumab

2014- cont. Principal Investigator Studio di fase III in pazienti con carcinoma del pancreas: nab-Paclitaxel + Gemcitabina vs Gemcitabina, come terapia adiuvante

2015- cont. Principal Investigator Studio osservazionale registro delle patologie pleuriche e del mesotelioma

2015- cont. Principal Investigator Studio multicentrico aperto con Herceptin@SCc + Perjeta@ + docetaxel in pazienti con carcinoma della mammella avanzato HER-2+

2015-cont. Principal Investigator Studio PREgnancy and FERtility - PREFERStudio osservazionale prospettico sulla preservazione della fertilità nelle pazienti giovani con patologia oncologica. PREFER (PREgnacy and FERtility) (PREFER).

2015-cont. Principal Investigator Studio osservazionale prospettico sul trattamento del carcinoma mmammario in gravidanza e sul follow-up delle donne che hanno avuto una gravidanza dopo diagnosi e trattamento di carcinoma mammario. (PREFER2)

2015-cont. Principal Investigator Studio clinico randomizzato, a gruppi paralleli, in aperto, di fase II per la valutazione degli effetti immunologici di tre regimi di vaccino GX301 in pazienti con tumore della prostata resistente alla terapia ormonale che hanno ottenuto una risposta alla prima linea di trattamento chemioterapico

2015-cont. Principal Investigator Studio clinico di fase III di confronto tra la somministrazione concomitante e quella sequenziale della chemioterapia e degli

inibitori dell' aromatasi come trattamento adiuvante delle pazienti in postmenopausa con carcinoma mammario operato ormonosensibile (GIM10).

2015-cont. Principal Investigator Studio di fase II a singolo braccio per la valutazione dell'efficacia e della sicurezza della combinazione di eribulina e bevacizumab come seconda linea di trattamento in pazienti con neoplasia mammaria metastatica HER2-negativa progredita ad un trattamento di prima linea con bevacizumab e paclitaxel (GIM11-BERG1).

2015-cont. Principal Investigator Studio di fase ii, randomizzato in aperto, multicentrico mirato a valutare l'attività della chemioterapia in associazione a trastuzumab e del lapatinib in associazione a trastuzumab in pazienti con carcinoma mammario metastatico her2-positivo (mbc), refrattari alle terapie anti-her2 (GIM12 Typher).

2015-cont. Principal Investigator Studio di Valutazione del trattamento (chemioterapico, terapia ormonale e terapia biologica) in pazienti affette da cancro al seno metastatico in accordo al sottotipo biologico e alla linea di trattamento (GIM14 BIOMETA).

2016-cont. Principal Investigator Studio Observation of Medical Treatments in MBC HER2-negative Patients (GIM13 AMBRA).

2016-cont. Chairman Studio su test diagnostico innovativo Oncotype DX® destinato a fornire, mediante analisi genomica del tumore, informazioni rispettivamente di tipo prognostico e predittivo circa il rischio di recidiva a 10 anni e sui benefici della chemioterapia adiuvante.

2016-cont. Principal Investigator Studio multicentrico, in aperto, a braccio singolo, teso a valutare la sicurezza di Herceptin in combinazione con Perjeta e Docetaxel nel trattamento di pazienti con carcinoma mammario avanzato Her2 positivo.

2016-cont. Principal Investigator Studio Fulvestrant seguito da everolimus più exemestane confrontato con exemestane più everolimus seguiti da fulvestrant in donne in postmenopausa affette da carcinoma mammario localmente avanzato o metastatico, positivo per l'espressione dei recettori ormonali (hr+) e negativo per quella del recettore del fattore di crescita epidermico tipo 2 (her2-), precedentemente trattate con inibitori dell'aromatasi non steroidei (nsai): uno studio multicentrico di fase III (GIM16 FEVEX). "

2016-cont. Principal Investigator A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma

2016-cont. Principal Investigator Studio di Valutazione della sodiemia e degli esiti della terapia correttiva in pazienti oncologici affetti da iponatremia secondaria a siadh di grado moderato e severo. studio prospettico osservazionale

2016-cont. Principal Investigator A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with

Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

2016-cont. Principal Investigator Translation, cross-Cultural adaptation and Validation of the US National Cancer Institute's Patient -Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for Italian-speaking cancer patients

2016-cont. Principal Investigator A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases.

2016-cont. Principal Investigator A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma

2016-cont. Principal Investigator Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma

2016-cont. Principal Investigator A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients carrying germline BRCA1/2 Mutations (SOLO3)

2016-cont. Principal Investigator A phase III, open-label, randomized study of atezolizumab (mpdl3280a, anti−pd-l1 antibody) in combination with carboplatin or cisplatin+pemetrexed compared with carboplatin or cisplatin+pemetrexed in patients who are chemotherapy-naive and have stage iv non-squamous non−small cell lung cancer.

2016-cont. Principal Investigator An Open-Label, Randomized Phase 3 Trial of Nivolumab versus platinum doublet chemotherapy and Nivolumab plus Ipilimumab versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

2016-cont. Principal Investigator Correlate – studio non interventistico sulla valutazione della sicurezza ed efficacia di regorafenib nell'ambito della pratica clinica di routine.

2016-cont. Principal Investigator A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

2017-cont. Principal Investigator Adjuvant treatment for high-risk triple negative breast cancer patients with the Anti-PD-L1 antibody Avelumab: A phase III randomized trial. (A-BRAVE-TRIAL).

2018-cont. Study Chairman Clinical study protocol GIM21 – LiqERBcept. Liquid Biopsy: intercepting mutational trajectories of HER2 breast cancer in patients under T-DM1 treatment

COMMISSIONI

1995 - 1997 Membro della Commissione Ministero Sanità su "Migrazioni Sanitarie in Oncologia".

1996 - 1997 Membro della Commissione CENSIS Ministero della Sanità per "La razionalizzazione della spesa sanitaria".

1997 - 1999 Membro della Commissione Ministeriale sui "Programmi di prevenzione primaria e secondaria del danno alla salute derivante dall'uso di prodotti di tabacco".

1997 - 1999 Membro della Commissione Nazionale per l'Oncologia per il triennio '97-'99.

1997 - 1999 Coordinatore del Gruppo di Lavoro n° 1 della Commissione Oncologica Nazionale "Aspetti e modelli organizzativi sottesi alla realizzazione ed organizzazione delle attività destinate alla tutela della salute in campo oncologico".

1997 - 1999 Membro del Gruppo di Lavoro n° 7 sulla ricerca oncologica della Commissione Oncologica Nazionale.

1998 - 2000 Membro della Commissione Oncologica Regionale.

2000 - 2002 Membro della Commissione Nazionale per l'Oncologia per il triennio 2000-'02.

2001 Nomine del Ministro dell'Ambiente e della Tutela del Territorio.

2001 - 2004 Vice Presidente Commissione Oncologica Regione Lazio.

2001 Gruppo di lavoro interministeriale (Salute, Ambiente e Comunicazioni) per elaborazione dossier campi di elettromagnetismo e radiofrequenze.

2001 Membro del gruppo di lavoro nelle infrastrutture e sui network di eccellenza a livello europeo nel campo della biosicurezza a biotecnologia nell'ambito del comitato nazionale per la biosicurezza e la biotecnologia.

2001 Coordinatore della Commissione Internazionale di studio ANPA per l'approfondimento della problematica del rischio sanitario connesso all'esposizione di campo magnetico.

2002 - 2005 Membro del Comitato Etico dell'Ospedale Sant'Andrea – Roma.

2002 - 2006 Membro del Consiglio Superiore di Sanità.

2002 - 2006	Segretario - Tesoriere dell'Associazione Alleanza contro il Cancro.
2004 - Cont.	Componente del Comitato Scientifico della rivista "Annali della sanità pubblica".
2004	Componente della delegazione italiana nel Comitato Multidisciplinare Permanente di supervisione delle attività di collaborazione Italia - Cina.
2004 - 2007	Componente del gruppo di lavoro per la certificazione delle biobanche.
2004 - 2005	Membro del gruppo di lavoro per il Comitato Nazionale per la Biosicurezza e le Biotecnologie "Gruppo per la certificazione delle biobanche".
2004 - 2006	Componente Commissione Oncologica Nazionale.
2005 - 2007	Fondatore e Membro Steering Committee European Alliance against Cancer.
2006	Componente Commissione Oncologica Regione Calabria.
2008 – 2009	Coordinatore del Gruppo di lavoro 1 / Rete Oncologica Regione Lazio "Organizzazione ed indirizzo della rete assistenziale e di ricerca clinica".
2008 - 2010	Membro della "Commissione di Programmazione" presso il Ministero del Lavoro, della Salute e delle Politiche Sociali.
2008 – 2010	Presidente Commissione Oncologica Regione Calabria.
2008 – 2012	Coordinatore del Gruppo Oncologico Nazionale del Ministero della Salute.
2008 – 2011	Coordinatore Scientifico per il gruppo di lavoro "Criteri di appropriatezza diagnostico terapeutici" per conto del Ministero del Lavoro, della Salute e delle Politiche Sociali.
2009 – 2011	Membro Comitato Ordinatore Reti – Ministero della Salute.
21/09/09 – 2011	Membro esperto della Commissione della Regione Calabria per le problematiche in merito alla presenza di navi contenenti rifiuti tossici e radioattivi nella zona di Cetraro / Paola.
2010 – 2012	Membro del Comitato Regionale e Coordinatore Macroarea 2 – Rete Oncologica Regione Lazio.
2010 – 2012	Membro del Comitato Etico Ospedale San Filippo Neri, Roma.
2010-2011	Membro del Comitato Etico Garante della Public Affairs Association-Relazioni Istituzionali in Sanità.
2011-2014	Esperto Consiglio Superiore di Sanità.
2011-2014	Presidente del Comitato Clinico-Scientifico Ospedale Israelitico, Roma.
2012–Cont.	Membro del Comitato Etico del Policlinico Umberto I – Roma

INCARICHI RIVISTE SCIENTIFICHE

2000 - Cont. Peer Reviewer of Annals of Oncology: Official Journal of the European Society for Medical Oncology.

2000 - 2003 Associate Editor of Tumori: Journal of Experimental and Clinical Oncology.

2004 - 2008 Peer Reviewer of International Journal of Cancer.

2012 - Cont. Editor in chief of "Reviews in Oncology"

2014- Cont. Peer Reviewer of Lancet Oncology

INSEGNAMENTI

1990 - Cont. Professore a contratto di Oncologia Clinica presso la II Scuola di Specializzazione in Oncologia dell'Università "La Sapienza" di Roma.

2001 - Cont. Presidente Consiglio Scientifico presso la Scuola Superiore di Oncologia.

2006 – 2007 Professore di Oncologia Medica presso la Scuola di Specializzazione in Ginecologia ed Ostetricia della Facoltà di Medicina e Chirurgia dell'Università "Campus Bio-Medico" di Roma.

PUBBLICAZIONI SU RIVISTE "PEER REVIEWED" (aggiornato 20.9.2019)

N° Pubblication on peer reviewed journals: 377 (PUBMED – WEB SCIENCE - Scopus - *dato rilevato in data 20.09.2019*)
Impact Factor totale : 4362,817
Impact factor medio per pubblicazione: 11,572 (scopus)
Citazioni Totali: 15152 (SCOPUS - dato rilevato in data 20.9.2019)
N° medio citazioni per pubblicazione: 40,190 (SCOPUS - dato rilevato in data 20.9.2019)
H – INDEX : 55 (SCOPUS - dato rilevato in data 20.9.2019)

1. *Correction to: Phase II study of weekly carboplatin in pretreated adult malignant gliomas.*
Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Carosi M, Casini B, Metro G, Maschio M, Koudriavtseva T, Cognetti F, Fabi A.
J Neurooncol. 2019 Sep 9. doi: 10.1007/s11060-019-03285-x I.F. = 3,06

2. *Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.*
Cortinovis D, Chiari R, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A.
Anticancer Res. 2019 Aug;39(8):4265-4271. doi: 10.21873/anticanres.13590 *I.F = 1,865*

3. *Phase II study of weekly carboplatin in pretreated adult malignant gliomas.*
Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Mariantonia C, Casini B, Metro G, Maschio M, Tatiana K, Cognetti F, Fabi A.
J Neurooncol. 2019 Aug;144(1):211-216. doi: 10.1007/s11060-019-03223-x. Epub 2019 Jul 4. J Neurooncol I.F. = 3,06

4. *Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer.*
Bazzichetto C, Conciatori F, Falcone I, Cognetti F, Milella M, Ciuffreda L.
J Oncol. 2019 May 5;2019:5373580. doi: 10.1155/2019/5373580. eCollection 2019. Review. I.F. = 3,333

5. *The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy.*
Fabi A, Lanzetta G, Vizza E, Corsi D, Moscetti L, Spinelli G, Mentuccia L, Lalle M, Perrone M, Baiocco L, Falcicchio C, Milani A, Giannarelli D, Cognetti F, Pugliese P.
Curr Probl Cancer. 2019 May 17. pii: S0147-0272(18)30341-6. doi: 10.1016/j.currproblcancer.2019.05.002 I.F. = 3,690

6. *Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.*
Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guizzaro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S.
Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24. I.F. = 4,54

7. *A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?*
Villani V, Fabi A, Tanzilli A, Pasqualetti F, Lombardi G, Vidiri A, Gonnelli A, Molinari A, Cantarella M, Bellu L, Terrenato I, Carosi M, Maschio M, Telera SM, Carapella CM, Cognetti F, Paiar F, Zagonel V, Pace A.
Future Oncol. 2019 May;15(15):1717-1727. doi: 10.2217/fon-2018-0826. Epub 2019 Apr 12. *I.F. = 2,369*

8. *Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.*
Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z IF = 8.676

9. *PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?*
Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F, Milella M, Ciuffreda L.
Cancers (Basel). 2019 Mar 28;11(4). pii: E435. doi: 10.3390/cancers11040435. Review.
I.F.=5.326

10. *RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.*
Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A.
J Exp Clin Cancer Res. 2019 Jan 8;38(1):12. doi: 10.1186/s13046-018-1001-2. Review IF=6,217

11. *Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.*
Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.
JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514. IF =20,871

12. *Role of mTOR Signaling in Tumor Microenvironment: An Overview.*
Conciatori F, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M, Ciuffreda L.
Int J Mol Sci. 2018 Aug 19;19(8). pii: E2453. doi: 10.3390/ijms19082453. Review.
I.F. = 3,687

13. *T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.*
Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F.
Breast. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12.
I.F = 2,951

14. *Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?*
Catania G, Malaguti P, Gasparro S, Cognetti F, Vidiri A, Fabi A.
Oncology. 2018;94 Suppl 1:29-33. doi: 10.1159/000489066. Epub 2018 Jul 24.
I.F. = 2,262

15. *Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.*
Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.

J Exp Clin Cancer Res. 2018 Jul 9;37(1):140. doi: 10.1186/s13046-018-0820-5.
I.F.= 6,217

16. *Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.*
De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.
BJU Int. 2018 Jun 29. doi: 10.1111/bju.14461.
I.F.= 4.668

17. *Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.*
Russillo M, Ferretti G, Vidiri A, Gasparro S, Cognetti F, Pellegrini D, Fabi A.
In Vivo. 2018 Jul-Aug;32(4):839-842. doi: 10.21873/invivo.11317.
I.F.= 1,116

18. *Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.*
Garassino MC, Gelibter AJ, Grossi F, Chiari R, Parra HS, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini EE, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.
J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553-7. doi: 10.1016/j.jtho.2018.04.025.
I.F. = 10,34

19. *Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.*
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
I.F. = 79,26

20. *Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.*
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.
Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.
I.F. = 36,421

21. *Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.*

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators.
Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.
I.F. = 36,421

22. *mTOR Cross-Talk in Cancer and Potential for Combination Therapy.*
Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M.
Cancers (Basel). 2018 Jan 19;10(1). pii: E23. doi: 10.3390/cancers10010023. Review.
I.F = 5,326

23. *Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?*
Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F.
Future Oncol. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28.
I.F. = 2,369

24. *Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.*
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.
Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.
I.F. = 36,421

25. *Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.*
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F.
Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8.
I.F. = 5.168

26. *Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.*
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
I.F.=79,26

27. *Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.*
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.
Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25
I.F. = 36,421

28. *Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.*
Ciuffreda L, Del Curatolo A, Falcone I, Conciatori F, Bazzichetto C, Cognetti F, Corbo V, Scarpa A, Milella M.
Ann Oncol. 2017 Nov 1;28(11):2896-2898. doi: 10.1093/annonc/mdx335
I.F. = 13,93

29. *Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.*
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.
Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.
I.F. = 7,191

30. *The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?*
Fabi A, Falcicchio C, Giannarelli D, Maggi G, Cognetti F, Pugliese P.
Breast. 2017 Aug;34:44-52. doi: 10.1016/j.breast.2017.04.012. Epub 2017 May 11.
I.F = 2,951

31. *Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.*
Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G.
Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21.
I.F = 5,306

32. *PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.*
*Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, **Cognetti F**, Del Bufalo D, Ciuffreda L.*
Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.
I.F. = 4,122

33. *Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.* *Giacinti S, Carlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, Aschelter AM, Felici A, Valeriani M,* ***Cognetti F****, Marchetti P. Anticancer Drugs. 2017 Jan;28(1):110-115.*
I.F. = 1,869

34. *Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.* *Lambertini M, Ceppi M,* ***Cognetti F****, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030.*
I.F. = 7,191

35. *Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC).* *Garufi C, Giacomini E, Torsello A, Sperduti I, Melucci E, Mottolese M, Zeuli M, Ettorre GM, Ricciardi T,* ***Cognetti F****, Magnani M, Ruzzo A. Sci Rep. 2016 Sep 26;6:34006. doi: 10.1038/srep34006.*
I.F. = 4,122

36. *First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?* *Fabi A, Malaguti P, Vari S,* ***Cognetti F****. J Exp Clin Cancer Res. 2016 Jun 30;35:104. doi: 10.1186/s13046-016-0380-5. Review.*
I.F. = 6,217

37. *Palbociclib: efficacious but predictive biomarkers still needed.*
Cognetti F*, Malaguti P, Alesini D.*
Lancet Oncol. 2016 Mar 2.pii: S1470-2045(16)00144-3.doi: 10.1016/S1470-2045(16)00144-3.
I.F.= 36,421

38. *Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.*
Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; GIM Study Group.
JAMA. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291.
I.F.= 47,661

39. *Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.*
Fabi A, Giannarelli D, Malaguti P, Ferretti G, Vari S, Papaldo P, Nisticò C, Caterino M, De Vita R, Mottolese M, Iacorossi L, ***Cognetti F****.*
Drug Des Devel Ther.2015 Nov 20;9:6177-83. doi: 10.2147/DDDT.S89575. eCollection 2015.
I.F. = 2,935

40. *Metastatic pancreatic cancer: Is there a light at the end of the tunnel?*

*Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, **Cognetti F**, Reni M, Milella M.*
World J Gastroenterol. 2015 Apr 28;21(16):4788-801.doi: 10.3748/wjg.v21.i16.4788. Review.
I.F.= 3,3

41. *PTEN: Multiple Functions in Human Malignant Tumors.*
*Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, **Cognetti F**, Ciuffreda L.*
Front Oncol. 2015 Feb 16;5:24. doi: 10.3389/fonc.2015.00024. eCollection 2015. Review
I.F. = 4,416

42. *Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.*
*Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, **Cognetti F**; for the Gruppo Italiano Mammella (GIM) investigators.*
Lancet. 2015 Feb 27. pii: S0140-6736(14)62048-1. doi: 10.1016/S0140-6736(14)62048-1.
I.F. = 53,254

43. *Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.*
*Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, Verde NL, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, **Cognetti F**, Giannarelli D.*
Future Oncol. 2015 Feb;11(3):431-8. doi: 10.2217/fon.14.271.
I.F. = 2,369

44. *First-line crizotinib versus chemotherapy in ALK-positive lung cancer.*
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators.
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
I.F. = 79,26

45. *Nivolumab in previously untreated melanoma without BRAF mutation.*
*Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, **Cognetti F**, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA.*
N Engl J Med. 2015 Jan 22;372(4):320-30.
I.F. = 79,26

46. *Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.*
*Bria E, Di Modugno F, Sperduti I, Iapicca P, Visca P, Alessandrini G, Antoniani B, Pilotto S, Ludovini V, Vannucci J, Bellezza G, Sidoni A, Tortora G, Radisky DC, Crinò L, **Cognetti F**, Facciolo F, Mottolese M, Milella M, Nisticò P.*
Oncotarget. 2014 Nov 30;5(22):11054-63.
I.F. = 5,168

47. *Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.*
*Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, **Cognetti F**, Tortora G, Milella M.*
Crit Rev Oncol Hematol. 2014 Aug 18. pii: S1040-8428(14)00133-4. doi: 10.1016/j.critrevonc.2014.08.001. [Epub ahead of print] Review.
I.F. = 4,495

48. *PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.*
*Ciuffreda L, Falcone I, Cesta Incani U, Del Curatolo A, Conciatori F, Matteoni S, Vari S, Vaccaro V,**Cognetti F**, Milella M.*
Adv Biol Regul. 2014 Sep;56:66-80. doi: 10.1016/j.jbior.2014.07.002. Epub 2014 Jul 19.
I.F. = 0

49. *Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.*
*Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, **Cognetti F**, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P.*
J Transl Med. 2014 May 7;12:116. doi: 10.1186/1479-5876-12-116.
I.F. = 4,197

50. *Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.*
*Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V,**Cognetti F**, Pompili A, Marucci L, Carapella CM, Pace A.*
Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.
I.F. = 2,583

51. *Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.*
*Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM, Antonuzzo A, **Cognetti F**, Ferraresi V, Ridolfi L, Guidoboni M, Guida M, Pigozzo J, Chiarion Sileni V.*
J Neurooncol. 2014 May;118(1):109-16. doi: 10.1007/s11060-014-1400-y. Epub 2014 Feb 16. I.F. = 3,06

52. *Targeting bone metastatic cancer: Role of the mTOR pathway.*
*Bertoldo F, Silvestris F, Ibrahim T, **Cognetti F**, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D.*
Biochim Biophys Acta. 2014 Apr;1845(2):248-54. doi: 10.1016/j.bbcan.2014.01.009. Epub 2014 Feb 5. Review.
I.F. = 8,22

53. *Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.*
*Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F,**Cognetti F**, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M.*
Cancer Invest.2014 May;32(4):144-9.doi: 10.3109/07357907.2014.885984.Epub 2014 Jan 31.

I.F. = 2,053

54. *KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.*
*Barone C, Pinto C, Normanno N, Capussotti L, **Cognetti F**, Falcone A, Mantovani L.*
PLoS One. 2014 Jan 20;9(1):e85897. doi: 10.1371/journal.pone.0085897. eCollection 2014.
I.F. = 2,766

55. *Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC.*
*Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, **Cognetti F**, McCubrey JA, Milella M.*
Curr Pharm Des. 2014;20(24):3944-57.
I.F. = 2,757

56. *Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.*
*Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, **Cognetti F**, Bria E, Milella M.*
Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3.
I.F. = 4,692

57. *Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.*
*Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, **Cognetti F**, Baldi A.*
Future Oncol. 2013 Sep;9(9):1375-88. doi: 10.2217/fon.13.99.
I.F = 2,369

58. Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.
*Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, **Cognetti F**, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L; Gruppo Italiano Mammella.*
Oncologist. 2013;18(8):924-5. doi: 10.1634/theoncologist.2013-0222. Epub 2013 Aug 12. Erratum in: Oncologist. 2013;18(10):1149.
I.F. = 5,306

59. *First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.*
*Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, **Cognetti F**, Milella M.*
World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511.
I.F. = 3,3

60. *Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.*
Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, ***Cognetti F****, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH Jr, Tassell V, Huang X, Paolini J, Kern KA, Romieu G.*
J Clin Oncol. 2013 Aug 10;31(23):2870-8.
I.F. = 26,36

61. *Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.*
Massari F, Bria E, Maines F, Milella M, Giannarelli D, ***Cognetti F****, Pappagallo G, Tortora G, Porta C.*
Clin Genitourin Cancer. 2013 Dec;11(4):471-6. doi: 10.1016/j.clgc.2013.04.018. Epub 2013 Jun 28.
I.F. = 2,539

62. *An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.*
Lazzaro C, Bordonaro R, ***Cognetti F****, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.*
Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013.
I.F. = 0

63. Single-dose Palonosetron and Dose-reduced Regimen of Dexamethasone in Preventing Nausea and Vomiting by Anthracycline-including Chemotherapy in Patients with Early Breast Cancer
By: Pacetti, Umberto; Veltri, Enzo; Fattorus, Silvia Ileana Sara; et al.
ANTICANCER RESEARCH Volume: 33 Issue: 4 Pages: 1721-1724 Published: APR 2013
I.F = 1,865

64. *Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.*
Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, ***Cognetti F****.*
BMC Cancer. 2013 Mar 28;13:164. doi: 10.1186/1471-2407-13-164.
I.F. = 3,288

65. *Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.*
Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, ***Cognetti F****, Mottolese M. Expert Opin Pharmacother. 2013 Apr;14(6):699-706.*
I.F. = 2014 3,475

66. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
Malaguti P, Vari S, ***Cognetti F****, Fabi A.*
Anticancer Res. 2013 Jan;33(1):21-8.
I.F. = 1,865

67. *Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.*
Felici A, Bria E, Tortora G, ***Cognetti F****, Milella M.*
Expert Rev Anticancer Ther. 2012 Dec;12(12):1545-57. doi: 10.1586/era.12.149.
I.F.= 2.347

68. *A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).*
Cognetti F*, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K.*
Gynecol Oncol. 2012 Dec 9.
I.F. = 4,54

69. *Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.*
Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C; ***TORCH Investigators.***
J Thorac Oncol. 2012 Dec;7(12):1830-44. doi: 10.1097/JTO.0b013e318275b327
I.F. = 10,34

70. *Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D,* ***Cognetti F****.*
BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482.
I.F. = 3,288

71. Therapeutic potential of MEK inhibition in acute myelogenous leucemia: rationale for "vertical" and "laterla" combination strategies.
Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, ***Cognetti F****, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M.*
J Mol Med (Berl). 2012 Oct;90(10):1133-44. Epub 2012 Mar 8
I.F. = 4,938

72. Molecular and genetic bases of pancreatic cancer.
Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, ***Cognetti F****, Novelli F, Nistico P, Milella M.*
Curr Drug Targets. 2012 Jun;13(6):731-4
I.F. = 3.112

73. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group. Clin Cancer Res. 2012 Apr 15;18(8):2290-300. Epub 2012 Feb 28
I.F. = 10,199

74. *EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.*

Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M, ***Cognetti F****.*
J Thorac Oncol. 2012 Apr;7(4):672-80.
I.F. = 10,34

75. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, ***Cognetti F****, Torrisi E, Crivellari D.*
Ann Oncol. 2012 Jun;23(6):1436-41. Epub 2011 Oct 29
I.F. = 13,93

76. .Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
Cognetti F*, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, Massidda B, Rubagotti A, Giannarelli D, Boccardo F; on behalf of the Study Group*
Ann Oncol. 2012 Mar;23(3):695-700. Epub 2011 Aug 22
I.F.= 13,93

77. Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience.
Adamo V, Ricciardi GR, De Placido S, Colucci G, Conte P, Giuffrida D, Gebbia N, Masci G, ***Cognetti F****, Dondi D, Venturini M.*
Eur J Cancer. 2012 Mar;48(5):642-7. Epub 2011 Jul 13
I.F. = 7,191

78. *Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V,* ***Cognetti F****, Tortora G, Falcone A, Bria E.*
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies.
Cancer. 2012 Mar 15;118(6):1523-32. doi: 10.1002/cncr.26460. Epub 2011 Aug 25
I.F. = 6,537

79. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.
Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, ***Cognetti F****, Del Bufalo D, Milella M.*
J Mol Med (Berl). 2012 Jan; . 90(6):667-79. Epub 2012 Jan 4.
I.F. = 4,938

80. Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.

Martinelli F, Quinten C, Maringwa JT, Coens C, Vercauteren J, Cleeland CS, Flechtner H, Gotay C, Greimel E, King M, Mendoza T, Osoba D, Reeve BB, Ringash J, Koch JS, Shi Q, Taphoorn MJ, Weis J, Bottomley A; European Organisation for Research and Treatment of Cancer Clinical Groups.
Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):587-99.
I.F. = 1,797

81. Emerging pathways and future targets for the molecular therapy of pancreatic cancer.
*Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, **Cognetti F**, Milella M.*
Expert Opin Ther Targets. 2011 Oct;15(10):1183-96.
I.F. = 4,598

82. Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
*Russillo M, Di Benedetto A, Metro G, Ferretti G, Papaldo P, **Cognetti F**, Mottolese M, Fabi A.*
J Clin Oncol. 2011 Jul 10;29(20):2834-5; author reply 2835. Epub 2011 Jun 13. No abstract available
I.F. = 26,36

83. *Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group.*
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N Engl J Med. 2011 Jun 30;364(26):2507-16. Epub 2011 Jun
I.F. = 79,26

84. *Caruso A, VignaC,Bigazzi V, Leone C, Maggi G, Martayan A,Sega FM, **Cognetti F**,Savarese A.*
Factors associated with an individuals' decision to withdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are personality traits involved?
Fam Cancer. 2011 Sep;10(3):581-9.
I.F. = 1,943

85. *Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, **Cognetti F**.*
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.
J Exp Clin Cancer Res. 2011 May 12;30:54.
I.F. = 6,217

86. *Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, Sperduti I, Gelibter A, Scagliotti GV, **Cognetti F**, Giannarelli D.*
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.
Ann Oncol. 2011 Oct;22(10):2277-85. Epub 2011 Feb 16. Review
I.F. = 13,93

87. *Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P,* ***Cognetti F****, Mottolese M.*
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.
Clin Cancer Res. 2011 Apr 1;17(7):2055-64. Epub 2011 Feb 9
I.F. = 10,199

88. *Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I,* ***Cognetti F****, Carapella CM.*
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center.
J Exp Clin Cancer Res. 2011 Jan 18;30:10
I.F. = 6,217

89. *Metro G, Giannarelli D, Gemma D, Lanzetta G, Ciccarese M, Papaldo P, Gamucci T, Lorusso V, Mottolese M, Magnolfi E,* ***Cognetti F****, Fabi A.*
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Breast J. 2010 Jan-Feb;16(1):66-72. Epub 2009 Nov 2.
I.F. = 2,424

90. *Vizza E, Pellegrino A, Milani R, Fruscio R, Baiocco E,* ***Cognetti F,*** *Savarese A, Tomao F, Chen C, Corrado G.*
Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy.
Eur J Surg Oncol. 2010 Dec 29. [Epub ahead of print
I.F.= 3,688

91. *Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nisticò C, Ruggeri EM, Sperduti I, Bracarda S, Pinnarò P, Lanzetta G, Muti P,* ***Cognetti F,*** *Carlini P*
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials.
BMC Cancer. 2010 Dec 9;10:675
I.F. = 3,288

92. *Garufi C, Torsello A, Tumolo S, Ettorre G M, Zeuli M, Campanella C, Vennarecci G, Mottolose M, Sperduti I,* ***Cognetti F.***
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Br J Cancer. 2010 Nov 9;103(10):1542-7. Epub 2010 Oct 19.
I.F. = 5,922

93. *Bria E, Carlini P, Cuppone F, Vaccaro V, Milella M,* ***Cognetti F.***
Early recurrence risk: aromatase inhibitors versus tamoxifen.
Expert Rev Anticancer Ther. 2010 Aug;10(8):1239-53
I.F.= 2.347

94. *Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crinò L, Papaldo P, Mottolese M,* ***Cognetti F,*** *Fabi A, Gori S.*

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011 Mar;22(3):625-30. Epub 2010 Aug 19.
I.F. = 13,93

95. *Vici P, Fabi A, Metro G, Sergi D, Giannarelli D, Di Lauro L, Bepler G, Tomao F,* ***Cognetti F,*** *Conti F, Lopez M.*
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
Cancer Chemother Pharmacol. 2011 Mar;67(3):687-93. Epub 2010 May 29.
I.F. = 2,808

96. *Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P, Sperduti I, Giannarelli D,* ***Cognetti F***
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials.
J Exp Clin Cancer Res. 2010 May 26;29:58.
I.F. = 6,217

97. *Campanella C, Mottolese M, Cianciulli A, Torsello A, Merola R, Sperduti I, Melucci E, Conti S, Diodoro MG, Zeuli M, Paoletti G,* ***Cognetti F,*** *Garufi C*
Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
J Transl Med. 2010 Apr 16;8:36.
I.F. = 4,197

98. *Fabi A, Metro G, Di Benedetto A, Nisticò C, Vici P, Melucci E, Antoniani B, Perracchio L, Sperduti I, Milella M,* ***Cognetti F****, Mottolese M*
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Oncology. 2010;78(2):141-9. Epub 2010 Apr 13.
I.F. = 2.262

99. *Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM,* ***Cognetti F****, Pace A.*
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
J Neurooncol. 2010 Mar 30. [Epub ahead of print]
I.F. = 3,06

100. *Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R,* ***Cognetti F****, Scher HI, Pandolfi PP.*
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
J Clin Invest. 2010 Mar 1;120(3):681-93. doi: 10.1172/JCI40535. Epub 2010 Feb 8
I.F. = 13,251

101. *Pace A, Giannarelli D, Galiè E, Savarese A, Carpano S, Della Giulia M, Pozzi A, Silvani A, Gaviani P, Scaioli V, Jandolo B, Bove L,* ***Cognetti F.***

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.
Neurology. 2010 Mar 2;74(9):762-6.
I.F. = 8.055

102. *Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R,* ***Cognetti F****; Thymosin Melanoma Investigation Group.*
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
J Clin Oncol. 2010 Apr 1;28(10):1780-7.
I.F. = 26,36

103. *Milella M, Gelibter AJ, Pino MS, Bossone G, Marolla P, Sperduti I,* ***Cognetti F.***
Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.
Oncologist. 2010;15(2):e1-4.
I.F. = 5,306

104. *Pasquini L, Petronelli A, Petrucci E, Saulle E, Mariani G, Scambia G, Benedetti-Panici P, Greggi S,* ***Cognetti F****, Testa U.*
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
Int J Oncol. 2010 Mar;36(3):707-13
I.F. = 3,333

105. *Ferraresi V, Nuzzo C, Zoccali C, Marandino F, Vidiri A, Salducca N, Zeuli M, Giannarelli D,* ***Cognetti F,*** *Biagini R.*
Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients.
BMC Cancer. 2010 Jan 28;10:22
I.F. = 3,288

106. *Caruso A, Vigna C, Marozzo B, Sega FM, Sperduti I,* ***Cognetti F,*** *Savarese A.*
Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers.
J Exp Clin Cancer Res. 2009 Dec 21;28:157.PMID: 20025726
I.F. = 6,217

107. *Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D,* ***Cognetti F****, Bepler G.*
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Cancer Invest. 2010 Feb;28(2):172-80
I.F. = 2,053

108. *Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A,* ***Cognetti F****, Carapella CM.*
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7.
I.F. = 2.808

109. *Ferretti G, Felici A,* ***Cognetti F****.*

Darbepoetin Alfa and History of Thromboembolic Events.
J Clin Oncol. 2009 Nov 20;27(33):e211; author reply e212. Epub 2009 Oct 26.
I.F.= 26,36

110. *Metro G, Giannarelli D, Gemma D, Lanzetta G, Ciccarese M, Papaldo P, Gamucci T, Lorusso V, Mottolese M, Magnolfi E,* ***Cognetti F****, Fabi A.*
Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer.
Breast J. 2009 Nov 2. [Epub ahead of print]
I.F. = 2,424

111. *Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators****(Cognetti F).***
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Lancet Oncol. 2009 Oct;10(10):943-9. Epub 2009 Aug 31.
I.F. : 36,421

112. *Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnarò P, Terzoli E,* ***Cognetti F****, Carlini P*
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Cancer. 2009 Aug 1;115(15):3446-56.
I.F. 6,537

113. *Milella M, Metro G, Gelibter A, Pino SM, Cognetti F, Fabi A.*
COX-2 targeting in cancer: a new beginning?
Ann Oncol. 2008 Jun;19(6):1209-10
I.F. 13,93

114. *Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S,* ***Cognetti F****, Buttitta F.*
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Neoplasia. 2009 Oct;11(10):1084-92.
I.F. = 4,994

115. *Petronelli A, Saulle E, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Greggi S,* ***Cognetti F****, Russo MA, Sporn M, Testa U.*
High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide.
Cancer Lett. 2009 Sep 18;282(2):214-28.
I.F. = 6,491

116. *Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Rivera SL, Boulware D, Cognetti F, Bepler G.*

In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy*.*
Cancer Invest. 2009 Aug 13:1.
I.F. = 2,053

117. *Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS; ESO-MBC Task Force.*
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
J Natl Cancer Inst. 2009 Sep 2;101(17):1174-81. Epub 2009 Aug 5. Review.
I.F. = 11,238

118. *Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnarò P, Terzoli E,* ***Cognetti F****, Carlini P.*
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Cancer. 2009 Aug 1;115(15):3446-56.
I.F. 6,537

119. *Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A,* ***Cognetti F****, Anichini A, Zupi G, Milella M.*
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Neoplasia. 2009 Aug;11(8):720-31.
I.F. = 4,994

120. *Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S,* ***Cognetti F****.*
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Anticancer Res. 2009 Jul;29(7):2607-10.
I.F. = 1.865

121. *Bria E, Di Maio M, Carlini P, Cuppone F, Giannarelli D,* ***Cognetti F****, Milella M.*
Targeting targeted agents: open issues for clinical trial design.
J Exp Clin Cancer Res. 2009 May 22;28:66. Review.
I.F. = 6,217

122. *Fabi A, Metro G, Russillo M, Vidiri A, Carapella CM, Maschio M,* ***Cognetti F****, Jandolo B, Mirri MA, Sperduti I, Telera S, Carosi M, Pace A.*
Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
BMC Cancer. 2009 Mar 31;9:101.
I.F. = 3.288

123. *Nisticò C, Bria E, Vaccaro V, Cuppone F, Fornier M, Sperduti I, Carpino A, Izzo F, Tropea F,* ***Cognetti F****, Terzoli E.*
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.

Anticancer Drugs. 2009 Feb;20(2):109-14.
I.F. = 1,869

124. *Bria E, Milella M, Sperduti I, Alessandrini G, Visca P, Corzani F, Giannarelli D, Cerasoli V, Cuppone F, Cecere FL, Marchetti A, Sacco R, Mucilli F, Malatesta S, Guetti L, Vitale L, Ceribelli A, Rinaldi M, Terzoli E,* ***Cognetti F****, Facciolo F.*
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer.
Lung Cancer. 2009 Mar 25. [Epub ahead of print]
I.F. = 4,486

125. *Felici A, Di Segni S, Milella M, Colantonio S, Sperduti I, Nuvoli B, Contestabile M, Sacconi A, Zaratti M, Citro G,* ***Cognetti F****.*
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Clin Pharmacokinet. 2009;48(2):131-41. doi: 10.2165/0003088-200948020-00005.
I.F. = 4.464

126. *Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, Bria E, Carpanese L, Ruggeri EM, Carlini P,* ***Cognetti F****.*
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Oncology. 2009;76(4):254-61. Epub 2009 Feb 26.
I.F. = 2.262

127. *Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D,* ***Cognetti F****, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F.*
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Oncology. 2009;76(1):49-54.
I.F. = 2.262

128. *Caruso A, Vigna C, Maggi G, Sega FM,* ***Cognetti F****, Savarese A.*
The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample.
J Exp Clin Cancer Res. 2008 Nov 24;27:75.
I.F. = 6,217

129. *Bria E, Cuppone F, Milella M, Verma S, Carlini P, Nisticò C, Vaccaro V, Rossi A, Tonini G,* ***Cognetti F****, Terzoli E.*
Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues.
Expert Opin Biol Ther. 2008 Dec;8(12):1963-71.
I.F. = 3.974

130. *Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S,* ***Cognetti F****, Di Leo A, Pronzato P, Crinó L, Agostara B, Conte P.*

Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Clin Breast Cancer. 2008 Oct;8(5):453-6.
I.F. = 2,703

131. *Nisticò P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, Aricò E, Valentini M, Bracci L,* ***Cognetti F****, Ciccarese M, Vercillo G, Roselli M, Fossile E, Tosti ME, Wang E, Marincola F, Imberti L, Catricalà C, Natali PG, Belardelli F, Proietti E.*
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.
Int J Cancer. 2009 Jan 1;124(1):130-9.
I.F. = 7,36

132. *Salesi N, Russillo M, Marandino F, Ruggeri EM, Metro G,* ***Cognetti F****, Fabi A*
Bone of the hands as unusual metastastatic site of renal cell carcinoma.
J Exp Clin Cancer Res. 2007 Dec;26(4):595-7.
I.F. = 6,217

133. *Torsello A, Garufi C, Cosimelli M, Diodoro MG, Zeuli M, Vanni B, Campanella C, D'Angelo C, Sperduti I, Perrone Donnorso R,* ***Cognetti F****, Terzoli E, Mottolese M; Colorectal Disease Management Team, Regina Elena Cancer Institute, Rome, Italy.*
P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance.
Eur J Cancer. 2008 Jun;44(9):1217-22.
I.F. = 7,191

134. *Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M,* ***Cognetti F****.*
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
Breast. 2008 Oct;17(5):499-505.
I.F. = 2,951

135. *Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group.*
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63. Epub 2008 Oct 7.
I.F. = 11,238

136. *Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group.*
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Lancet. 2008 Jul 12;372(9633):117-26.
I.F. = 53,254

137. *Cuppone F, Bria E, Carlini P, Milella M, Felici A, Sperduti I, Nisticò C, Terzoli E,* ***Cognetti F****, Giannarelli D.*
Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
Cancer. 2008 Jul 15;113(2):238-46.
I.F. 6,537

138. *Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group.*
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90.
I.F. : 79,26

139. *Milella M, Metro G, Gelibter A, Pino SM,* ***Cognetti F****, Fabi A.*
COX-2 targeting in cancer: a new beginning?
Ann Oncol. 2008 Jun;19(6):1209-10.
I.F. = 13,93

140. *Fabi A, Ciccarese M, Metro G, Savarese A, Giannarelli D, Nuzzo CM, Russillo M, Sperduti I, Carbone I, Bria E,* ***Cognetti F****.*
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.
Support Care Cancer. 2008 Dec;16(12):1375-80.
I.F. = 2,676

141. *Metro G, Fabi A, Russillo M, Papaldo P, De Laurentiis M, Ferretti G, Pellegrini D, Nuzzo C, Graziano V, Vici P, Introna M, Felici A,* ***Cognetti F****, Carlini P.*
Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
Anticancer Res. 2008 Mar-Apr;28(2B):1245-58. Review.
I.F. = 1,865

142. *Nuzzo C, Zeuli M, Ferraresi V, Ciccarese M, Pelligrini D,* ***Cognetti F****.*
Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma.
Anticancer Res. 2008 Mar-Apr;28(2B):1429-31.
I.F. = 1,865

143. *Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti I, Carlini P, Terzoli E,* ***Cognetti F****, Giannarelli D.*
Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials.
Lung Cancer. 2009 Jan;63(1):50-7. Epub 2008 Jun 18.
I.F. = 4,486

144. *Bria E, Cuppone F, Fornier M, Nistico C, Carlini P, Milella M, Sperduti I, Terzoli E,* ***Cognetti F****, Giannarelli D.*

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Breast Cancer Res Treat. 2008 May;109(2):231-9.
I.F. = 3,605

145. *Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M,* ***Cognetti F****, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R.*
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
J Natl Cancer Inst. 2008 Mar 19;100(6):388-98. Epub 2008 Mar 11.
I.F. = 11,238

146. *Ferraresi V, Ciccarese M, Cercato MC, Nuzzo C, Zeuli M, Di Filippo F, Giannarelli D,* ***Cognetti F.***
Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study.
Cancer Chemother Pharmacol. 2008 Dec;63(1):149-55.
I.F. = 2.808

147. *Gelibter AJ, Zeuli M,* ***Cognetti F****, Di Segni S.*
Bevacizumab: one treatment for all the seasons?
J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. Erratum in: J clin Oncol 2008 Apr10;26(11)1911.
I.F. = 2,808

148. *Ferretti F, Felici A, Cognetti F*
HER2 and response to paclitaxel in node-positive breast cancer
N Engl J Med 2007; 357: 1496-506.
I.F. = 79,26

149. *Ferretti G, Felici A,* ***Cognetti F****.*
HER2 and response to paclitaxel in node-positive breast cancer.
N Engl J Med. 2008 Jan 10;358(2):197; author reply 198.
I.F. : 79,26

150. *Metro G, Sperduti I, Russillo M, Milella M,* ***Cognetti F,*** *Fabi A.*
Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Oncologist. 2007 Dec;12(12):1467-9; author reply 1469-71.

I.F. = 5,306

151. *Ferretti G, Felici A,* ***Cognetti F.***
The protective side of progesterone.
Breast Cancer Res. 2007;9(6):402.
I.F. = 6,142

152. *Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M,* ***Cognetti F.***
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25.
I.F. = 2,808

153. *Pino MS, Gamucci T, Mansueto G, Trapasso T, Narducci F, Giampaolo MA, Fariello AM, Sperduti I, Ceribelli A,* ***Cognetti F.***
A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Lung Cancer. 2008 Jun;60(3):381-6.
I.F. = 4,486

154. *Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi S, Carlini P, Milella M, Nisticò C, Terzoli E,* ***Cognetti F****, Giannarelli D.*
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Cancer. 2008 Jan 15;112(2):260-7.
I.F. = 6,537

155. *Ferretti G, Fabi A, Carlini P, Papaldo P, Felici A, Tomao S,* ***Cognetti F.***
Zoledronic acid and angiogenesis.
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6850; author reply 6850-1
I.F. = 10,199

156. *Fabi A, Mirri A, Felici A, Vidiri A, Pace A, Occhipinti E,* ***Cognetti F****, Arcangeli G, Iandolo B, Carosi MA, Metro G, Carapella CM.*
Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.
J Neurooncol. 2008 Mar;87(1):79-84. Epub 2007 Nov 7.
I.F. = 3,06

157. *Ferretti G, Felici A,* ***Cognetti F.***
Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy.
J Natl Cancer Inst. 2007 Nov 7;99(21):1644; author reply 1644-6. Epub 2007 Oct 30.
I.F.: 11,238

158. *Ferretti G, Felici A,* ***Cognetti F****, Mandala M.*
Transforming growth factor-beta signaling and regulatory T cells.
J Clin Oncol. 2007 Oct 10;25(29):4695-6; author reply 4696-7.

I.F. = 26,36

159. *Ferretti G, Felici A, Carlini P,* ***Cognetti F.***
Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.
J Natl Cancer Inst. 2007 Sep 19;99(18):1416. Epub 2007 Sep 11.
I.F.: 11,238

160. *Nisticò C, Bria E, Cuppone F, Fornier M, Sperduti I, Carpino A, Pace A,* ***Cognetti F,*** *Terzoli E.*
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Anticancer Drugs. 2007 Jul;18(6):687-92.
I.F. = 1,869

161. *Ferretti G, Felici A, Carlini P,* ***Cognetti F.***
Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial.
J Natl Cancer Inst. 2007 Sep 5;99(17):1344-5. Epub 2007 Aug 28.
I.F.: 11,238

162. *Gelibter AJ, Gamucci T, Pollera CF, Costanzo FD, Nuzzo C, Gabriele A, Signorelli C, Gasperoni S, Ferraresi V, Giannarelli D,* ***Cognetti F****, Zeuli M.*
A phase II trial og gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Curr Med Res Opin. 2007 Sep;23(9):2117-23.
I.F. = 2,665

163. *Rochè H, Yelle L,* ***Cognetti F****, Mauriac L, Bunnell C, Sprarano J, Kerbrat P, Delord JP, Vahadat L, Peck R, Lebwohl D, Ezzeddine R, Curè H.*
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone Banalog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
J Clin Oncol. 2007 Aug 10;25(23):3415-20.
I.F. = 26,36

164. *Ferretti G, Felici A,* ***Cognetti F.***
The other side of p53.
Ann Oncol. 2007 Aug;18(8):1425-6.
I.F. = 13,93

165. Bria E, Visca P, Novelli F, Casini B, Diodoro MG, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M, Cecere FL, Cognetti F, Mottolese M.
Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
Eur J Surg Oncol. 2008 May;34(5):593-8.
I.F. = 3,688

166. *Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nistico C, Cuppone F, Metro G, Terzoli E,* ***Cognetti F****, Ferretti G.*
Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36.
I.F. = 3,883

167. *Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nistico C, Terzoli E,* ***Cognetti F****, Giannarelli D.*
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress?: a meta-analysis of 20 phase 3 trials.
Cancer. 2007 Aug 1;110(3):525-33.
I.F. 6,537

168. *Ferretti G, Fabi A, Carlini P, Papaldo P, Felici A,* ***Cognetti F****.*
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Bone. 2007 Jul;41(1):155-6. Epub 2007 Apr 21.
I.F. = 4,455

169. *Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P,* ***Cognetti F****, Testa A, Di Maio M, Morabito A, Perrone F, GECO investigators.*
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the Gemcitabine-COxib in NSCLC (GECO) study.
Lancet Oncol. 2007 Jun;8(6):500-12.
I.F. = 36,421

170. *Ferretti G, Felici A, Carlini P,* ***Cognetti F****.*
Exemestane or tamoxifen?
Lancet. 2007 May 12;369(9573):1599; author reply 1600-1.
I.F. = 53,254

171.<u>A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells</u>
Petrucci, Eleonora; Pasquini, Luca; Petronelli, Alessia; et al.
GYNECOLOGIC ONCOLOGY Volume: 105 Issue: 2 Pages: 481-492 Published: MAY 2007
IF = 4,54

172. *Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L,* ***Cognetti F****, Tafuri A, Milella M.*
Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
Drug Resist Updat. 2007 Jun;10(3):81-100. Epub 2007 May 7.
I.F. = 11,63

173. *Bria E, Cuppone F, Cecere FL, Milella M, Nistico C,* ***Cognetti F****, Terzoli E.*
Adjuvant chemotherapy for non-small cell lung cancer.

J Thorac Oncol. 2007 May;2(5 Suppl):S7-11.
I.F. = 10,34

174. *Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P, Fabi A, Ruggeri EM, Milella M, Alimonti A, Salesi N,* ***Cognetti F****.*
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Cancer Invest. 2007 Mar;25(2):102-5.
I.F. = 2,053

175. *Ferretti G, Felici A,* ***Cognetti F****.*
RE: Age-related lobular involution and risk of breast cancer.
J Natl cancer Inst. 2007 Apr 4;99(7):571-2; author reply 572.
I.F.= 11,238

176. *Ferretti G, Felici A,* ***Cognetti F****.*
Pregnancy levels of estrogen and progesterone: the double-edged sword.
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):634; author reply 634-5
I.F. = 4,554

177. *Gelibter AJ, Zeuli M, Di Segni S, Milella M, Ferretti G, Nuzzo C,* ***Cognetti F****.*
Old age: "Biological" versus "Chronological".
J Clin Oncol. 2007 Feb 20;25(6).
I.F. = 26,36

178. *Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, Biffoni M, Ferretti G, Benedetti-Panici P,* ***Cognetti F****, Scambia G, Humphreys R, Peschle C, Testa U.*
A small molecole Snac mimis potentiates TRAIL-mediated cell death of ovarian cancer cells.
Gynecol Oncol. 2007 May;105(2):481-92.
I.F.= 4,540

179. *Bria E, Di Maio M, Cuppone F, Nistico C,* ***Cognetti F****, Giannarelli D.*
Sholud subgroup analysis of randomized clinical trias have a direct impact on clinical practice?
J Clin Oncol. 2007 Feb 10;25(5):605-6.
I.F. = 26,36

180. *Ferretti G, Bria E, Giannarelli D, Felici A, Mandala M, Ciccarese M, Papaldo P, Fabi A,* ***Cognetti F****.*
Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
Thromb Res. 2007;119(4):525-9.
I.F. = 2,779

181. *Bria E, Ruggeri EM, Pollera CF, Terzoli E,* ***Cognetti F****.*
Adjuvant chemotherapy for bladder cancer: the chance for metaanalyses comparison
Eur Urol. 2007 Feb;51(2):576-7.
I.F. = 17,851

182. G*asparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A,* ***Cognetti F****, Lambiase A, Amadori D.*

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Breast Cancer Res Treat. 2007 Mar;101(3):355-65.
I.F. = 3,605

183. *Ferretti G, Giannarelli D, Carlini P, Felici A, Ciccarese M, Mandala M,* ***Cognetti F****.*
Self-monitoring versus standard monitoring of oral anticoagulation.
Thromb Res. 2007;119(3):389-90.
I.F. = 2,779

184. *Nistico C, Bria E, Cuppone F, Carpino A, Ferretti G, Vitelli G, Sperduti I, Calabretta F, Toglia G, Tomao S,* ***Cognetti F****, Terzoli E.*
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients.
Anticancer Drugs. 2007 Feb;18(2):227-32.
I.F. = 1,869

185. *Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, Papaldo P, Fabi A, Ciccarese M, Cuppone F, Cecere FL, Nuzzo C, Terzoli E,* ***Cognetti F****.*
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?
Chest. 2006 Dec;130(6):1808-16.
I.F. = 7,652

186. *Ferraresi V, Catricala C, Ciccarese M, Ferrari A, Zeuli M,* ***Cognetti F****.*
Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
Anticancer Res. 2006 Nov-Dec;26(6C):4771-4.
I.F. = 1,865

187. *Ferretti G, Felici A, Papaldo P, Fabi A,* ***Cognetti F****.*
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62.
I.F. = 2,821

188. *Bria E, Carlini P,* ***Cognetti F****, Terzoli E, Giannarelli D.*
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
J Natl Cancer Inst. 2007 Jan 17;99(2):176-7.
I.F.= 11,238

189. *Ceribelli A, Pino MS, Gelibter AJ, Milella M, Cecere FL, Caterino M, Facciolo F, Mirri A,* ***Cognetti F.***
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Cancer. 2007 Feb 15;109(4):727-31.
I.F. = 6,537

190. *Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P,* ***Cognetti F****, Humphreys R, Peschle C, Testa U.*

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Apoptosis. 2007 Apr;12(4):635-55.
I.F. = 3,967

191. *Mottolese M, Orlandi G, Sperduti I, Merola R, Buglioni S, Di Benedetto A, Pinnaro P, Perracchio L, Venturo I,* ***Cognetti F****, Cianciulli A.*
Bio-pathologic Characteristics Related to Chromosome 11 Aneusomy and Cyclin D1 Gene Status in Surgically Resected Stage I and II Breast Cancer: Identification of an Adverse Prognostic Profile.
Am J Surg Pathol. 2007 Feb;31(2):247-254.
I.F. = 5,878

192. *Fabi A, Nuzzo C,Vidiri A, Ciccarese M, Pino S, Felici A, Cattani F,* ***Cognetti F****.*
Bone and lung metastates from intracranial meningioma.
Anticancer Res. 2006 Sep-Oct;26(5B):3835-7.
I.F. = 1,865

193. *Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foà R,* ***Cognetti F****, Tafuri A, Andreeff M.*
MEK blockade converts AML differentiating response to retinoids into extensive apoptosi.
Blood. 2007 Mar 1;109(5):2121-9.
I.F. = 15,132

194. *Nisticò C, Cuppone F, Bria E, Fornier M, Giannarelli D, Mottolese M, Novelli F, Natoli G,* ***Cognetti F****, Terzoli E.*
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
Anticancer Drugs. 2006 Nov;17(10):1193-200.
I.F. = 1,869

195. *Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G,* ***Cognetti F****, Sacchi A, Baldi A.*
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6133-43.
I.F. = 10,199

196. *Ferretti G, Felici A, Pino MS,* ***Cognetti F****.*
Does CTL4 influence the suppressive effect of CD25+CD4+ regulatory T cells?
J Clin Oncolo. 2006 Dec 1;24(34):5469-70; author reply 5470-1.
I.F. = 26,36

197. *Ferretti G, Alimondi A,* ***Cognetti F****.*
Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?
Br J Cancer. 2006 Nov 6;95(9):1304-5; author reply 1306-7.
I.F. = 5,922

198. *Gelibter AJ, Lo nardi S, Di Segni S, Fontana A, Loupakis F,* ***Cognetti F****, Labianca R.*
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
J Clin Oncol. 2006 Oct 1;24(28):4668-9; author reply 4669.

I.F. = 26,36

199. *Spugnini EP, Bosari S, Citro G, Lorenzon I,* ***Cognetti F****, Baldi A.*
Human malignat mesothelioma: molecular mechanism of pathogenesis and progression
Int J Biochem Cell Biol. 2006;38(12):2000-4.
I.F. = 3,247

200. *Ferretti G, Felici A,* ***Cognetti F****.*
Controversies on autoimmunity and prognosis in cancer.
Br J Cancer. 2006 Sep 18;95(6):763; author reply 764-5.
I.F. = 5,922

201. *Ferretti G, Lopez M, Terzoli E, Cortesi E, Antimi M, Marolla P, Giannarelli D,* ***Cognetti F****, Papaldo P.*
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?
J Clin Oncol. 2006 Dec 10;24(35):5618-9.
I.F. = 26,36

202. *Carlini P, Papaldo P, Fani A, Felici A, Ruggeri EM, Milella M, Ciccarese M, Nuzzo C,* ***Cognetti F****, Ferretti G.*
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
J Clin Oncol. 2006 Dec 10;24(35):e60-1.
I.F. = 26,36

203. *Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, Izzo F, Terzoli E,* ***Cognetti F****, Giannarelli D.*
Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Cancer Treat Rev. 2006 Dec;32(8):583-7. Epub 2006 Aug 21.
I.F. = 8,122

204. *Ferretti G, Papaldo P,* ***Cognetti F****.*
Lineage-specific hematopoietic growth factors.
N Engl J Med. 2006 Aug 3;355(5):526; author reply 527.
I.F. = 79,26

205. *Ferretti G, Papaldo P, Fabi A, Carlini P, Felici A,* ***Cognetti F****.*
Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.
Oncologist. 2006 Jul-Aug;11(7):853-4.
I.F. = 5,306

206. *Fabi A, Vidiri A, Ferretti G, Felici A, Papaldo P, Carlini P, Mirri A, Nuzzo C,* ***Cognetti F****.*
Dramatic regression of multiple brain metastases from breast cancer with capecitabine: another arrow at the bow?
Cancer Invest. 2006 Jun-Jul;24(4):466-8.
I.F. = 2,053

207. *Papaldo P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, Cortesi E, Antimi M, Terzoli E, Carlini P, Vici P, Botti C, Di Lauro L, Naso G, Nisticò C, Mottolese M, Di Filippo F, Ruggeri EM, Ceribelli A,* ***Cognetti F****.*
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
J Clin Oncol. 2006 Jul 1;24(19):3048-55.
I.F. = 26,36

208. *Bria E, Di Maio M, Nisticò C, Cuppone F, Terzoli E,* ***Cognetti F****, Giannarelli D.*
Factorial design for randomized clinical trials.
Ann Oncol. 2006 Oct;17(10):1607-8.
I.F. = 13,93

209. *Bria E, Ciccarese M, Giannarelli D, Cuppone F, Nisticò C, Nuzzo C, Natoli G, Fabi A, Terzoli E,* ***Cognetti F****, Carlini P.*
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8.794 patients
Cancer Treat Rev. 2006 Aug;32(5):325-32.
I.F. = 8,122

210. *Merola R, Mottolese M, Orlandi G, Vico E,* ***Cognetti F****, Sperduti I, Fabi A, Vitelli G, Cianciulli AM.*
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis.
Eur J Cancer. 2006 Jul;42(10):1501-6.
I.F. = 7,191

211. *Ferretti G, Fabi A, Carlini P, Papaldo P, Felici A,* ***Cognetti F****.*
What is the biological significance of circulating blood levels of metalloproteinases?
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3550-1; author reply 3551.
I.F. = 10,199

212. *Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M,* ***Cognetti F****, Zupi G, Milella M.*
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Cancer Res. 2006 Jun 1;66(11):5549-54.
I.F. = 9,13

213. *Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Di Cosimo S, Ruggeri EM, Milella M, Ciccarese M, Cecere FL, Gelibter A, Nuzzo C,* ***Cognetti F****, Terzoli E, Carlini P.*
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.
Br J Cancer. 2006 Jun 19;94(12):1789-96.
I.F. = 5,922

214. *Ferretti G, Felici A, Papaldo P, Carlini P, Fabi A,* ***Cognetti F****.*
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.

Oncologist. 2006 May;11(5):533; author reply 534.
I.F. = 5,306

215. *Ferretti G, Felici A,* ***Cognetti F****, Mandala M.*
Is there a right-sided shift for colorectal cancer in women compared with men?
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1054.
I.F. = 4,554

216. *Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Papaldo P, Fabi A, Ciccarese M,* ***Cognetti F****.*
Does low-molecular-weight heparin influence cancer-related mortality?
Ann Oncol. 2006 Oct;17(10):1604-6.
I.F. = 13,93

217. *Bria E, Nisticò C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E,* ***Cognetti F****, Giannarelli D.*
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Cancer. 2006 Jun 1;106(11):2337-44.
I.F. = 6,537

218. *Ferretti G, Felici A,* ***Cognetti F****.*
Ras oncogene mutations and survival in patients with lung cancer.
Br J Cancer. 2006 May 22;94(10):1548; author reply 1549.
I.F. = 5,922

219. *Bria E, Ceribelli A, Trovò MG, Gelibter A, Gigante M, Calabrò E, Cuppone F,* ***Cognetti F****, Terzoli E, Pastorino U.*
Non-small-cell lung cancer: early stages
Ann Oncol. 2006 Mar;17 Suppl 2:ii17-21.
I.F. = 13,93

220. *Pino SM, Shrader M, Baker CH,* ***Cognetti F****, Xion HQ, Abruzzese JL, McConkey DJ.*
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Cancer Res. 2006 Apr 1;66(7):3802-12.
I.F. = 9,13

221. *Ceribelli A, Cecere FL, Milella M, Facciolo F, Gelibter A,* ***Cognetti F****.*
Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.
Lancet Oncol. 2006 Apr;7(4):353.
I.F. = 36,421

222. *Rosell R, Cecere F,* ***Cognetti F****, Cuello M, Sanchez JM, Taron M, Reguart N, Jablons D.*
Future directions in the second-line treatment of non-samll cell lung cancer.
Semin Oncol. 2006 Feb;33(1 Suppl 1):S45-51.

I.F. = 4,942

223. *Ruggeri EM, Giannarelli D, Bria E, Carlini P, Felici A, Nelli F,* ***Cognetti F****, Pollera CF.*
Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies.
Cancer. 2006 Feb 15;106(4):783-8.
I.F. = 6,537

224. *Papaldo P, Fabi A, Ferretti G, Mottolese M, Cianciulli AM, Di Cocco B, Pino MS, Carlini P, Di Cosimo S, Sacchi I, Sperduti I, Nardoni C,* ***Cognetti F****.*
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-postive disease.
Ann Oncol. 2006 Apr;17(4):630-6.
I.F. = 13,93

225. *Ferretti G, Felici A, Ciccarese M, Papaldo P, Carlini P, Fabi A, Gelibter A,* ***Cognetti F****.*
Molecular stool testing for the early detection of colorectal cancer: swan song for p53?
Ann Oncol. 2006 Jun;17(6):1026.
I.F. = 13,93

226. *Di Costanzo F, Gasperoni S, Papaldo P, Bilancia D, Manzione L, Landucci E, Mazzoni F,* ***Cognetti F****.*
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose finding trial of GOIRC & GOL
Ann Oncol. 2006 Jan;17(1):79-84.
I.F. = 13,93

227. *Ferretti G, Bria E, Felici A, Carlini P, Giannarelli D, Ciccarese M, Papaldo P, Fabi A, Gelibter A,* ***Cognetti F****.*
Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?
Ann Oncol. 2006 Mar;17(3):528-9.
I.F. = 13,93

228. *Garufi C, Vanni B, Aschelter AM, Zappala AR, Bria E, Nisticò C, Sperduti I,* ***Cognetti F****, Terzoli E.*
Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Eur J Cancer. 2006 Mar;42(5):608-16
I.F. = 7,191

229. *Fabi A, Ferretti G, Papaldo P, Salesi N, Ciccarese M, Lorusso V, Carlini P, Carpino A, Mottolese M, Cianciulli AM, Giannarelli D, Sperduti I, Felici A,* ***Cognetti F****.*
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients.
Cancer Chemother Pharmacol. 2006 May;57(5):615-23.
I.F. = 2,808

230. *Ferretti G, Carlini P, Bria E, Felici A, Giannarelli D, Ciccarese M, Papaldo P, Fabi A,* ***Cognetti F****.*
Chemotherapy-induced amenorrhea in early breast cancer.
Ann Oncol. 2006 Feb;17(2):352.
I.F. = 13,93

231. *Papaldo P, Di Cosimo S, Ferretti G, Carlini P, Fabi A, Cecere F,* ***Cognetti F****.*
Is anthracycline based chemotherapy alone adeguate for young women with estrogen receptor-positive breast cancer?
Breast. 2006 Apr;15(2):269-72.
I.F. = 2,951

232. *Felici A, Carlini P, Ruggeri EM, Gamucci T, Pollera CF, De Marco SD, Fariello AM, Moscetti L, Gelibter A, Adami E, Sperduti I,* ***Cognetti F****.*
BI-Weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Cancer Chemother Pharmacol. 2006 Jan;57(1):59-64.
I.F. = 2,808

233. Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab
Van Cutsem, E.; Labianca, R.; Cognetti, F.; et al.
TARGETED ONCOLOGY Volume: 1 Issue: 1 Pages: 2-12 Published: JAN 2006
IF = 3,907

234. Adjuvant systemic therapies in patients with colorectal cancer: An audit on clinical practice in Italy
By: Roila, Fausto; Ruggeri, Benedetta; Ballatori, Enzo; et al.
Group Author(s): Drug Utilization Review Team Onco
TUMORI Volume: 91 Issue: 6 Pages: 472-476 Published: NOV-DEC 2005
IF 2016= 1,23

235. *Fabi A, Salesi N, Vidiri A, Mirri A, Ferraresi V,* ***Cognetti F****.*
Retroperitoneal liposarcoma with metastasis to both orbits: an unusual metastatic site.
Anticancer Res. 2005 Nov-Dec;25(6C):4769-71.
I.F. = 1,865

236. *Pino MS, Nawrocki ST,* ***Cognetti F****, Abruzzese JL, Xiong HQ, McConkey DJ.*
Prostaglandin E(2) drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells.
Cancer Biol Ther. 2005 Nov;4(11):1263-9.
I.F. 3,373

237. *Alimonti A, Ferretti G,* ***Cognetti F****.*
Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?
J Clin Oncol. 2005 Dec 1;23(34):8918; author reply 8918-9.
I.F. = 26,36

238. *Fabi A, Salesi N, Di Cocco B, Vidiri A, Visca P, Pace A, Carapella C, De Paola U, Mirri A,* ***Cognetti F****.*
Choroid plexus carcinoma in the adult: is there a role for chemotherapy?

J Exp Clin Cancer Res. 2005 Sep;24(3):493-6.
I.F. = 6,217

239. *Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Papaldo P, Nisticò C, Fabi A, Cuppone F, Gelibter A, Terzoli E,* ***Cognetti F****.*
Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: is there any difference in cancer-related mortality?
J Clin Oncol. 2005 Oct 1;23(28):7248-50; author reply 7250.
I.F. = 26,36

240. *Gelibter A, Ceribelli A, Pollera CF, Milella M, Moscetti L, Sperduti I,* ***Cognetti F****.*
Impact of gefitinib ("Iressa") treatment on the quality of life of patients with advanced non-small-cell lung cancer.
J Cancer Res Clin Oncol. 2005 Dec;131(12):783-8.
I.F. = 3,282

241. *Ferraresi V, Ciccarese M, Zeuli M,* ***Cognetti F****.*
Central nervous system as exclusive site of disease in patients with melanoma: treatment and clinical outcome of two cases.
Melanoma Res. 2005 Oct;15(5):467-9.
I.F. = 3,135

242. *Spugnini EP, Bosari S, Citro g, Lorenzon I,* ***Cognetti F****, Baldi A.*
Human malignant mesothelioma: molecular mechanisms of pathogenesis and progressione
Int J Biochem Cell Biol. 2006;38(12):2004-4.
I.F. = 3,247

243. *Bogliolo A, Russel-Edu W, Alloro G, Ballarini R, Bocchini G, Cecere L, Codonesu A, Cognetti G, Montella M, Ricci R, Seroppi P, Trocino A, Truffelli R,* ***Cognetti F****, Truccolo I.*
More information, more choice: an Italian database for oncology patients
Ann Oncol. 2005 Dec;16(12):1962-7.
I.F. = 13,93

244. *Salesi N, Carlini P, Ruggeri EM, Ferretti G, Bria E,* ***Cognetti F****.*
Prostate cancer: the role of hormonal therapy.
J. Exp Clin Cancer Res 2005, 24,2:175-180.
I.F. = 6,217

245. *Alimonti A, Nardoni C, Papaldo P, Ferretti G, Caleno MP, Carlini P, Fabi A, Rasio D, Vecchione A,* ***Cognetti F****.*
Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.
Anticancer Res. 2005 Sep-Oct;25(5):3531-2.
I.F. = 1,865

246. *Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P, Fabi A, Nisticò P, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M, Terzoli E,* ***Cognetti F****.*
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma.

Cancer. 2005 Oct 1;104(7):1335-42.
I.F.= 6,537

247. *Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cisimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D'Agosto G, Bordignon V, Trento E,* ***Cognetti F****.*
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Oncology. 2005;69(1):35-43.
I.F.= 2.262

248. *Gelibter A, Malaguti P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre GM, Pellicciotta M, Giannarelli D, Terzoli E,* ***Cognetti F****, Milella M.*
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.
Cancer. 2005 Sep 15;104(6):1237-45.
I.F. = 6,537

249. *Nisticò C,* ***Cognetti F****, Frontini L, Barni S, Ferretti G, Bria E, Milella M, Garufi C, Cuppone F, Vanni B, Carlini P, Terzoli E.*
Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.
Oncology. 2005;68(4-6):356-63.
I.F.= 2.262

250. *Marty M,* ***Cognetti F****, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM.*
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patiens with human epidermal growth factor receptor 2-positive metastatic breast cancer administererd as firts-line treatment: the M77001 study group.
J Clin Oncol. 2005 Jul 1;23(19) 4265-74.
I.F. = 26,36

251. *Ferretti G, Bria E, Carlini P, Felici A, Giannarelli D, Cuppone F, Papaldo P, Nisticò C, Fabi A, Gelibter A, Terzoli E,* ***Cognetti F****.*
Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?
Gut. 2005 Jun;54(6):891.
I.F. = 17,016

252. *Ruggeri EM, Carlini P, Pollera F, De Marco S, Riuscito P, Pinnarò P, Nardi M, Giannarelli D,* ***Cognetti F****.*
Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery.
Head Neck. 2005 Jun;27(6):452-8.
I.F. = 2,471

253. *Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Ruggeri EM, Alimonti A, Nardoni C,* ***Cognetti F****.*

Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukemia in breast cancer women?
Ann Oncol. 2005 Jul;16(7):1209-10.
I.F. = 13,93

254. *Ferretti G, Mandalà M, Bria E, Papaldo P, Carlini P, Fabi A, Milella M, Ruggeri EM, Nisticò C,* ***Cognetti F****.*
Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?
Ann Oncol. 2005 Aug;16(8):1403-4.
I.F. = 13,93

255. *Ferretti G, Mandala M, Bria E, Carlini P, Papaldo P, Fabi A, Felici A,* ***Cognetti F****.*
Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer.
Breast Cancer Res Treat. 2005 Apr;90(3):319.
I.F. = 3,605

256. *Fabi A, Ferretti G, Salesi N, Papaldo P, Carlini P, Ciccarese M, Di Cocco B, Cecere F, Nardoni C, Felici A,* ***Cognetti F****.*
Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
Ann Oncol. 2005 Mar;16(3):516-7.
I.F. = 13,93

257. *Bria E, Giannarelli D, Felici A, Peters WP, Nisticò C, Vanni B, Cuppone F,* ***Cognetti F****, Terzoli E.*
Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma.
Cancer. 2005 Feb 15;103(4):672-9.
I.F. 6,537

258. *Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A,* ***Cognetti F****, Zangemeister-Wittke U, Del Bufalo D, Zupi G.*
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene amplified breast cancer cells.
Clin Cancer Res. 2004 Nov 15;10(22):7747-56.
I.F. = 10,199

259. *Papaldo P, Di Cosimo S, Ferretti G, Vici P, Marolla P, Carlini P, Fabi A,* ***Cognetti F****.*
Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients.
Cancer Invest. 2004;22(4):650-3.
I.F. = 2,053

260. *Ferretti G, Petti MC, Carlini P, Zeuli M, Picardi A, Meloni G, Bria E, Papaldo P, Fabi A,* ***Cognetti F****.*
Zoledronic acid-associated thrombotic thrombocytopenic purpura.
Ann Oncol. 2004 Dec;15(12):1847-8.
I.F. = 13,93

261. *Gelibter A, Milella M, Ceribelli A, Zeuli M, Ferraresi V, Vecchione A,* ***Cognetti F****.*
PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.
Anticancer Res. 2004 Sep-Oct;24(5B):3147-51.
I.F. = 1,865

262. *Terzoli E, Nisticò C, Fabi A, Milella M, Bria E, D'Ottavio AM, Vaccaro A, Vanni B, Garufi C, Ferraresi V, Giannarelli D, Papapldo P, Carlini P, Izzpo F,* ***Cognetti F****.*
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.
J Exp Clin Cancer Res. 2004 Jun;23(2):207-13.
I.F. = 6,217

263. *Fabi A, Vidiri A, Carapella C, Pace A, Occhipinti E, Caroli F, Mirri A, Carlini P,* ***Cognetti F****.*
Bone metastasis from glioblastoma multiforme without central nervous system relapse: a case report.
Anticancer Res. 2004 Jul-Aug;24(4):2563-5.
I.F. = 1,865

264. *Alimonti A, Gelibter A, Pavese I, Satta F,* ***Cognetti F****, Ferretti G, Rasio D, Vecchione A, Di Palma M.*
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Cancer Treat Rev. 2004 Oct;30(6):555-62.
I.F. = 8,122

265. *Di Cosimo S, Ferretti G, Milella M, Martinelli E, Alimonti A, Papaldo P, Carlini P, Fabi A, Matar P,* ***Cognetti F****.*
Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa).
Minerva Med. 2004 Jun;95(3):233-41.
I.F. =2.863

266. *Fabi A, Papaldo P, Pino MS, Ferretti G, Carlini P, Pacetti U, Di Cosimo S, Nardoni C, Giannarelli D, Sacchi I,* ***Cognetti F****.*
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
Anticancer Res. 2004 May-Jun;24(3b):1963-7.
I.F. = 1,865

267. *Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E,* ***Cognetti F****.*
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Cancer, 2004 Jul 1; 101(1): 133-8.
I.F. = 5,238

268. *Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandala M, Milella M, Ruggeri EM,* ***Cognetti F****.*
Incidence of chemotherapy-induced amenorrea depending on the timing treatment by menstrual cycle phase in women with early breast cancer.
Ann. Oncol. 2004 Jul; 15(7): 1065-71.
I.F. = 13,93

269. *Di Cocco B, Salesi N, Fabi A, Nardoni C, Ferretti G, Bossone G, Ciccarese M, Savarese A, Vecchione A,* ***Cognetti F****.*
Alfa-epoietin and anaemia in gynaecological cancer.
Anticancer Res. 2004 Mar-Apr;24(2C):1287-92.
I.F. = 1,865

270. *Salesi N, Fabi A, Di Cocco B, Marandino F, Pizzi G, Vecchione A,* ***Cognetti F****.*
Testis metastasis as an initial manifestation of an occult gastrointestinal cancer.
Anticancer Research, 2004 Mar-Apr, 24(2C): 1093-6.
I.F. = 1,865

271. *Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pelliciotta M, Ceribelli A, De Marco S, Facciolo F,* ***Cognetti F****.*
The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
J. Exp. Clin. Cancer Res. 2004 Mar; 23(1): 25-32.
I.F. = 6,217

272. *Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M,* ***Cognetti F****, Bourhis J, Kirkpatrick A, Van Glebbeke M; European Organization for Research and Treatment of Cancer Trial 22931.*
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
N. Engl. J. Med. 2004 May 6; 350 (19): 1945-52.
I.F. = 79,26

273. *Botti C, Buglioni S, Benevolo M, Giannarelli D, Papaldo P,* ***Cognetti F****, Vici P, Di Filippo F, Del Nonno F, Venanzi FM, Natali PG, Mottolese M.*
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
Clin Cancer Res. 2004 Feb 15;10(4):1360-5.
I.F. = 10,199

274. *Ferretti G, Di Cosimo S, Giannarelli D, Carlini P, Papaldo P, Alimonti A, Fabi A, Mandala M, Milella M, Ruggeri EM,* ***Cognetti F****.*
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
J Clin Oncol. 2004 Feb 1;22(3):568-9.
I.F. = 26,36

275. Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetogenic potential: Antiemetic prescriptions and incidence of emesis
By: Pignata, S; Tamboro, R; Barletta, E; et al.
Group Author(s): Italian Grp Antiemetic Res
TUMORI Volume: 90 Issue: 1 Pages: 103-106 Published: JAN-FEB 2004
IF 2016= 1,233

276. *Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Intergroup Exemestane Study. (****Cognetti F****.)*

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
N Engl J Med. 2004 Mar 11;350(11):1081-92. Erratum in: N Engl J Med. 2004 Dec 2;351(23):2461.
I.F. = 79,26

277. *Savarese A,* ***Cognetti F****.*
New drugs in the treatment of recurrent or metastatic cervical cancer.
Crit Rev Oncol Hematol. 2003 Dec;48(3):323-7.
I.F. = 4,494

278. *Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P,* ***Cognetti F****.*
Docetaxel in advanced gastric cancer-review of the main clinical trias.
Acta Oncol. 2003;42(7):693-700.
I.F. = 3,473

279. *Gelibter A, Ceribelli A, Milella M, Mottolese M, Vocaturo A,* ***Cognetti F****.*
Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) in non small cell lung cancer.
J Exp Clin Cancer Res. 2003 Sep;22(3):481-5.
I.F. = 6,217

280. *Carlini P, Di Cosimo S, Ferretti G, Papaldo P, Fabi A, Ruggeri EM, Milella M,* ***Cognetti F****.*
Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin.
Ann Oncol. 2003 Nov;14(11):1689-90.
I.F. = 13,93

281. *Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M,* ***Cognetti F****, Tonato M; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators.*
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer.
J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61.
I.F.= 11,238

282. *Alimonti A, Ferretti G, Di Cosimo S,* ***Cognetti F****, Vecchione A.*
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
J Clin Oncol. 2003 Sep 15;21(18):3543-4; author reply 3544-5.
I.F. = 26,36

283. *Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, Giannarelli D,* ***CognettiF****.*
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.
Ann Oncol. 2003 Sep;14(9):1378-82.
I.F. = 13,93

284. *Carlini P, Ferretti G, Di Cosimo S, Colella E, Tonachella R, Romiti A, Tomao S, Frassoldati A, Papaldo P, Fabi A, Ruggeri EM,* ***Cognetti F****.*
Is there a benefit by the sequenze anastrozole-formestane for postmenopausal metastatic bresta cancer women?
J Steroid Biochem Mol Biol. 2003 Jul; 86(1): 107-9.
I.F. = 4,095

285. *Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S, Bisagni G, Porrozzi S,* ***Cognetti F****, Di Costanzo F, Canaletti R, Ruggeri EM, Camisa R, Pucci F; Italian Oncology Group for Clinical Research.*
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-flourouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Ann Oncol. 2003, Aug; 14 (8): 1258-63.
I.F. = 13,93

286. *Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni M, Antimi M, Maione P, Migliorino MR, Giannarelli D,* ***Cognetti F****.*
Prolonged gemcitabine infusion in advanced non-small cell lung cancer: a randomized phase II study of two different schedules in combination with cisplatin.
Cancer, 2003, Jul 15;98(2):337-43.
I.F. = 6.537

287. *Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A,* ***Cognetti F****.*
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Drugs Today (Barc). 2003 Mar;39(3):157-74.
I.F. = 1,325

288. *Fabi A, Barduagni M, Lauro S, Portalone L, Mauri M, Marinis F, Narduzzi C, Tonini G, Giampaolo M, Pacetti U, Paoloni F,* ***Cognetti F****.*
Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observation study.
Support Care Cancer 2003, Mar; 11(3):156-61.
I.F. = 2,676

289. *Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B,* ***Cognetti F****, Bove L.*
Neuroprotective effect of vitamine E supplementation in patients treated with cisplatin chemotherapy.
J Clin Oncol. 2003, Mar 1;21(5):927-31.
I.F. = 26,36

290. *Leonetti C, Biroccio A, Gabellini C, Scarsella M, Maresca V, Flori E, Bove L, Pace A, Stoppacciaro A, Zupi G,* ***Cognetti F****, Picardo M.*
Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy.
Int J Cancer. 2003 Mar 20;104(2):243-50.
I.F. = 7,36

291. *Savarese A,* ***Cognetti F****.*
Perspectives in the clinical management BRCA mutations carriers.
J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):31-5.
I.F. = 6,217

292. *Ferretti G, Di Cosimo S, Carlini P, Papaldo P, Fabi A,* ***Cognetti F****.*
Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer.
J Natl Cancer Inst. 2002 Nov 20;94(22):1720; author reply 1721-2.
I.F.= 11,238

293. *Arcangeli G, Saracino B, Danesi DT, De Campora E, Giovinazzo G,* ***Cognetti F****, Carlini P, Arcangeli S, Mecozzi A.*
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer.
Am J Clin Oncol. 2002 Oct;25(5):431-7.
I.F. = 3,424

294. *Serrone L, Nardoni C, Gelibter A, Felici A,* ***Cognetti F****.*
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience Survey.
J Exp Clin Cancer Res. 2002 Jun;21(2):181-4.
I.F. = 6,217

295. *Boogaerts M, Coiffier B, Kainz C, Epoetin QOL Working Group,* ***Cognetti F****.*
Impact of epoetin b on quality of life in patients with malignant disease.
Br. J. Cancer 2003, 88, 988-995.
I.F. = 5.922

296. *Papaldo P, Cognetti F.*
The ATAC Trialists' Group. Arimidex, Tamoxifen alone or in combination.
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Lancet 22, 359 (9324), 2126-7, 2002.
I.F. = 53.254

297. *Zeuli M, Costanzo ED, Sdrobolini A, Gasperoni S, Paoloni FP, Carpi A, Moscetti L, Cherubini R,* ***Cognetti F****; Gruppo Oncologico Italiano per la Ricerca (GOIRC) and Gruppo Oncologico Laziale (GOL).*
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Ann Oncol. 2001 Dec;12(12):1737-41.
I.F. = 13,93

298. *Carlini P, Frassoldati A, De Marco S, Casali A, Ruggeri EM, Nardi M, Papaldo P, Fabi A, Paoloni F,* ***Cognetti F****.*
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

Ann Oncol. 2001 Nov;12(11):1539-43.
I.F. = 13,93

299. *Serrone L, Zeuli M, Papaldo P, Nardoni C, Pacetti U,* ***Cognetti F****.*
Ifosfamide and epirubicin combination in untreated sarcomas: two treatment-schedules.
Onkologie. 2001 Oct;24(5):465-8.
I.F. 2015 = 1,522

300. *D'Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, Carone MD, Abbolito MR, Carlini S, Perri P, Ricciotti A, Botti C, Conti F, Vici P, Rossi Chiappetta NR,* ***Cognetti F****, Buonomo O, Guadagni F.*
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
Breast Cancer Res Treat. 2001 Jul;68(1):9-19.
I.F. = 3,605

301. *Bernardo G, Aglietta M, Amadori D, Beccaglia P, Belli G, Bianco R, Cionini L,* ***Cognetti F****, Colucci G, Di Costanzo F, Marchetti P, Pronzato P.*
Prevalance of anemia in oncologic patients treated with chemotherapy. Italian survey at the national level.
Recenti Prof. Med. 2001 Oct;92(10):580-8.
I.F.= 0

302. *Nardi M, De Marco S, Fabi A, Aloe A, Magnani E, Pacetti U, Carlini P, Ruggeri EM,* ***Cognetti F****.*
Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Cancer Chemother Pharmacol. 2001 Sep;48(3):255-8.
I.F. = 2,808

303. *Venturini M, Michelotti A, Papaldo P, Del Mastro L, Bergaglio M, Lionetto R, Lunardi G, Sguotti C, Frevola L, Donati S, Rosso R,* ***Cognetti F****.*
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Ann Oncol. 2001 Aug;12(8):1097-106. Erratum in: Ann Oncol 2001 Oct;12(10):1498.
I.F. = 13,93

304. *Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D'Alessandro R, Carone MD, Cicchetti A, Ricciotti A, Venturo I, Perri P, Di Filippo F,* ***Cognetti F****, Botti C, Roselli M.*
A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
Clin Cancer Res. 2001 Aug;7(8):2357-62.
I.F. = 10,199

305. *Serrone L, Zeuli M, Gamucci T, Nardi M,* ***Cognetti F****.*
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.

I.F. = 2,808

306. *Zeuli M, Pino MS,* ***Cognetti F****.*
Capecitabine in the treatment of colorectal cancer.
Tumori. 2001 Jan-Feb;87(1 Suppl 1):S55-6.
I.F. 2016 = 1,233

307. ***Cognetti F****.*
Oncology in the year 2000: renewal and innovation. Introduction.
Tumori. 2000 Nov-Dec;86(6 Suppl 1):S5-6.
I.F. 2016 = 1,233

308. *Nardi M, De Marco S, Fabi A, Aloe A, Magnani E, Grandinetti P,* ***Cognetti F****.*
Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study.
Cancer Chemother Pharmacol. 2000;45(6):513-5.
I.F. = 2,808

309. *Serrone L, Zeuli M, Sega FM,* ***Cognetti F****.*
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
J Exp Clin Cancer Res. 2000 Mar;19(1):21-34.
I.F. = 6,217

310. *Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nisticò C, Thorel MF, Marsella A, Carpino A, Giannarelli D, Terzoli E,* ***Cognetti F****.*
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Am J Clin Oncol. 2000 Apr;23(2):132-9.
I.F. = 3,424

311. *De Santis S, Pace A, Bove L,* ***Cognetti F,*** *Properzi F, Fiore M, Triaca V, Savarese A, Simone MD, Jandolo B, Manzione L, Aloe L.*
Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor.
Clin Cancer Res. 2000 Jan;6(1):90-5.
I.F = 10,199

312. *Campisi C, Fabi A, Papaldo P, Massidda B, Zappalà A, Ionta MT,* ***Cognetti F****.*
Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.
Cancer Chemother Pharmacol. 1999;44 Suppl:S1-4
I.F= 2,808

313. *Scinto AF, Ferraresi V, Milella M, Tucci E, Santomaggio C, Pasquali-Lasagni R, Del Vecchio MR, Campioni N, Nardi M,* ***Cognetti F****.*
Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study.
Br J Cancer. 1999 Nov;81(6):1031-6.
I.F.= 5,922

314. *De Marco S, Pollera CF,* ***Cognetti F****.*

Nephroblastoma in the adult.
Med Pediatr Oncol. 1999 Nov;33(5):497-9.
I.F. = 0

315. Awareness of disease among Italian cancer patients: Is there a need for further improvement in patient information?
By: Ruggeri, B; Ballatori, E; Casali, P; et al.
Group Author(s): Italian Grp Evaluation Outcomes Onco
ANNALS OF ONCOLOGY Volume: 10 Issue: 9 Pages: 1095-1100 Published: SEP 1999
IF = 13,93

316. *Milella M, Nisticò C, Ferraresi V, Vaccaro A, Fabi A, D'Ottavio AM, Botti C, Giannarelli D, Lopez M, Cortesi E, Foggi CM, Antimi M, Terzoli E,* ***Cognetti F****, Papaldo P.*
Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women.
Breast Cancer Res Treat. 1999 Jun;55(3):259-66.
I.F. = 3,605

317. *De Marco S, Fabi A, Ceribelli A, Carlini P, Pollera CF,* ***Cognetti F****.*
Does pain at tumor site during vinorelbine infusion affect treatment of recurrent head and neck cancer patients.
Ann Oncol. 1999 Jul;10(7):865-6.
I.F. = 13,93

318. *The Italian Study Group for the Di Bella Multitherapy Trials.*
The unconventional Di Bella cancer treatment: a reflection on the Italian experience.
Cancer 86, 1903-1910, 1999.
I.F. = 6.537

319. ***Cognetti F*** *et al for the Italian Group for Evaluation of Outcomes in Oncology (I.G.E.O.)*
Patient compliance with quality of life questionnaires.
Tumori, 85: 92-95 1999.
I.F. 2016 = 1,233

320. *Passalacqua R and other contributors (****Cognetti F****)*
Patients' opinions, feelings and attitudes after a campaign to promote the Di Bella therapy.
Lancet, 353: 1310-1314, 1999.
I.F. : 36,421

321. ***Cognetti F*** *et al, on behalf of The Italian Study Group for the Di Bella Multitherapy Trials.*
Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy.
Br Med J, 318: 224-228, 1999.
I.F.=23.562

322. *Boccardo F, Rubagotti A, Canobbio L, Galligioni E, Sorio R, Lucenti A,* ***Cognetti F****, Ruggeri E, Landonio G, Baiocchi C, Besana C, Citterio G, De Rosa M, Calabresi F.*
Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomised phase II trial.

Tumori. 1998 Sep-Oct;84(5):534-9.
I.F. 2016 = 1,233

323. *Van Cutsem E, Pozzo C, Starkhammer H, Dirix L, Terzoli E,* ***Cognetti F****, Humblet Y, Garufi C, Filez L, Gruia G, Cote C, Barone C.*
A phase II study of irinotecan alternated with five-days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Ann Oncol. 1998 Nov;9(11):1199-204.
I.F. = 13,93

324. *vCampisi C, Fabi A, Papaldo P, Tomao S, Massidda B, Zappalà A, Ionta MT,* ***Cognetti F.***
Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.
Ann Oncol. 1998 May;9(5):565-7.
I.F. = 13,93

325. *Nardi M, Aloe A, De Marco S,* ***Cognetti F****, Iacovelli A, Atlante A, Calabresi F.*
Paclitaxel as salvage therapy in advanced pretreated ovarian cancer.
Am J Clin Oncol. 1997 Jun;20(3):230-2.
I.F. = 3,424

326. *Zeuli M, Cognetti F.*
Locally advanced colon cancer: the role of chemotherapy.
J Exp Clin Cancer Res, 16: 235-236, 1997.
I.F. = 6,217

327. *Cognetti F.*
Topotecan, un nuovo farmaco per il trattamento del carcinoma dell'ovaio e del microcitoma del polmone.
Tumori, Suppl. 2 to vol 83:1-2, 1997.
I.F. 2016 = 1,233

328. *Roila F, Palladino Ma, Picciafuoco M, De Angelis V, Ballatori E, Del Favero A, Tonato M,* ***Cognetti F****, for the Italian Group for the Antiemetic Research.*
Ondansetron + Dexamethasone versus Metoclopramide + Dexamethasone in the prevention of cisplatin induced delayed emesis.
J Clin Oncol, Jan 15:1, 124-130, 1997.
I.F. = 26,36

329. *Roila F,* ***Cognetti F*** *on behalf of the Italian Group for Antiemetic Research.*
Ondansetron versus Metoclopramide both combined with Dexamethasone in the prevention of Cisplatin-induced delayed emesis.
J Clin Oncol., 15: 124-30, 1997.
I.F. = 26,36

330. *Roila F,* ***Cognetti F*** *on behalf of the Italian Group for Antiemetic Research.*
Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients?
Ann Oncol, vol. 8: 561-567, 1997.
I.F. = 13,93

331. *Verveij J, De Mulder PH, de Graeff A, Vermorken JB, Wildiers J, Kerger J, Schornagel J,* ***Cognetti F****, Kirkpatrick A, Sahmoud T, Lefebre JL.*

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.
Ann Oncol. 1996 Oct;7(8):867-9.
I.F. = 13,93

332. *Gridelli C, Perrone F, Palmeri S, D'aprile M, **Cognetti F**, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR.*
Mitomycin C plus vindesine plus etoposide (MEV) vs mitomycin C plus vindesine plus cisplatin (MVP) in stage non-samll-cell lugn cancer: phase III multicentre reandomised Trial. The "Gruppo Oncologico Centro-Sud-Isole" (GOCSI).
Ann Oncol. 1996 Oct;7(8):821-6.
I.F. = 13,93

333. *Fauser AA, Duclos B, Chemaissani A, Del Favero A, **Cognetti F**, Diaz-Rubio E, Cortes-Funes H, Conte PF, Dressler H.*
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Eur J Cancer. 1996 Aug;32A(9):1523-9.
I.F. = 7,191

334. *Botti C, Vici P, Lopez M, Psaila A, Cavaliere F, Sega FM, Scinto AF, **Cognetti F**, Sciarretta F, Cavaliere R.*
Prognostic role of axillary lymphadenectomy in locally advanced breast carcinoma treated with neoadjuvant high-dose epirubicin.
J. Chemother, vol. 8, suppl.n.4, 265-268, 1996.
I.F. = 1,490

335. *Gebbia V, Mantovani G, Agostara B, Contu A, Farris A, Colucci G, **Cognetti F**, Restivo G, Speciale R, Ferrero B, et al.*
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-Fluorouracil: a multicenter phase II trial.
Ann Oncol. 1995 Dec;6(10):987-91.
I.F. = 13,93

336. *Scinto AF, Ferraresi V, Campioni N, Tonachella R, Piarulli L, Sacchi I, Giannarelli D, **Cognetti F**.*
Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Ann Oncol. 1995 Sep;6(7):665-71.
I.F. = 13,93

337. *Botti C, Vici P, Lopez M, Scinto AF, **Cognetti F**, Cavaliere R.*
Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
J Am Coll Surg. 1995 Sep;181(3):202-8.
I.F. = 4,767

338. *Schornagel JH, Verweij J, de Mulder PH,* ***Cognetti F****, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, de Graeff A, Clavel M, et al.*
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study.
J Clin Oncol. 1995 Jul;13(7):1649-55.
I.F. = 26,36

339. *Fabi A, Tonachella R, Savarese A, Cirulli S, Tomao S, Conte E,* ***Cognetti F****.*
A Phase II trial of vinorelbina and thiotepa in metastatic breast cancer.
Ann Oncol. 1995 Feb;6(2):187-9.
I.F. = 13,93

340. *Roila F, Tonato M, Del Favero A,* ***Cognetti F****, Cirulli S, Ferraresi V, Fabi A, Colella E et al, for the Italian Group for the Antiemetic Research.*
Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy.
J Clin Oncol. 9, 2417-2426, 1995.
I.F. = 26,36

341. *Roila F, Tonato M, Del Favero A,* ***Cognetti F****, Cirulli S, Colella E, Milella M, Savarese A, Stani S et al the Italian Group for the Antiemetic Research.*
Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis.
Ann Oncol 6, 805-810, 1995.
I.F. = 13,93

342. *Roila F, De Angelis V, Del Favero A, Chiara S,* ***Cognetti F****, Ferraresi V, Sabbatini R, Donati D, Ricci S, Nunziati F, Panza MT, on behalf of the Italian Group For The Antiemetic Research and Smith Kline Beecham – Italy.*
Dexamethasone, Granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer.
New Engl J Med 332, 1-5 1995.
I.F. = 79,26

343. *Pinnarò P, Cercato MC, Giannarelli D, Carlini P, Del Vecchio MR, Impiombato FA, Marzetti F, Milella M,* ***Cognetti F****.*
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Ann Oncol. 1994 Jul;5(6):513-9.
I.F. = 13,93

344. *Clavel M, Vermorken JB,* ***Cognetti F****, Cappelaere P, de Mulder PHM, Schornagel JH, Thueni EA, Verweij J, Wildiers J, Clerico M, et al.*
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell cancer of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.

Ann Oncol. 1994 Jul;5(6):521-6.
I.F. = 13,93

345. *De Mulder PHM, Cappelaere P,* ***Cognetti F****, Verweij J, Schornagel JH, Vermorken JB, Kirkpatrick A, Lefebvre JL.*
A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.
Cancer Chemother Pharmacol. 1994;33(5):438-40.
I.F.= 2,808

346. *Scinto AF, Cercato MC, Botti C, Tonachella R, Ferraresi V, Del Bianco S, Sacchi I,* ***Cognetti F****.*
Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.
Eur J Cancer. 1994;30A(9):1285-8.
I.F. = 7,191

347. *Colella E, Merlano M, Blengio F, Angelini F, Ausili Cefaro GP, Scasso F, Lo Russo V, Cirulli S, Giannarelli D,* ***Cognetti F****.*
Randomized phase II study of methotreaxte (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.
Eur J Cancer. 1994;30A(7):928-30.
I.F. = 7,191

348. *Roila F, Tonato M, Ballatori E, Olivieri A, Del Favero A,* ***Cognetti F*** *et al for the Italian Group For Antiemetic Research.*
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles.
Ann Oncol. 5 : 585-589, 1994.
I.F. = 13,93

349. *Favalli G, Roila F, Tonato M, De Angelis V, Ballatori E,* ***Cognetti F*** *et al, for the Italian Group for the Antiemetic Research.*
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer.
Support Care Cancer 2:167-170, 1994.
I.F. = 2,676

350. *De Angelis V, Ballatori E, Roila F, Tonato M,* ***Cognetti F*** *et al, for the Italian Group for the Antiemetic Research.*
On the relationship between nausea and vomiting in patients undergoing chemotherapy.
Support Care Cancer 2: 171-176, 1994.
I.F. = 2,676

351. *Vermorken JB, Verweij J, de Mulder PH,* ***Cognetti F****, Clavel M, Rodenhuis S, Kirkpatrick A, Snow GB.*
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.
Ann Oncol. 1993 Nov;4(9):785-8.
I.F. = 13,93

352. *Del Favero A, Ballatori E, Olivieri A, Tonato M, Roila F,* ***Cognetti F*** *et al for the Italian Group for the Antiemetic Research.*
Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy.
J Clin Oncol 11: 2396-2404, 1993.
I.F. = 26,36

353. *Schornagel JH, Verweij J, de Mulder PH,* ***Cognetti F****, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, Clavel M, Kirkpatrick A, et al.*
A phase II trial of 10-ethyl-10 deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cooperative Group.
Ann Oncol. 1992 Mar;3(3):223-6.
I.F. = 13,93

354. *Roila F, Tonato M, Favalli G, Ferraris C, Bolis C,* ***Cognetti F****, Cercato MC, Buzzi F, Del Rio S et al, for the Italian Group for Antiemetic Research.*
Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis.
Lancet July 11, 340: 96-99, 1992.
I.F. = 36,421

355. *Roila F, Tonato M,* ***Cognetti F****, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, et al.*
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
J Clin Oncol. 1991 Apr;9(4):675-8.
I.F. = 26,36

356. *Cercato MC, La Ferla G, Pericoli N, Scinto AF, Sacchi I,* ***Cognetti F****.*
Cardiac tamponade as the initial manifestation of an extracardiac malignancy.
Eur J Cancer. 1991;27(5):670-1.
I.F. = 7,191

357. *Verweij J, Schornagel J, de Mulder P, Henzen-Logmans S,* ***Cognetti F****, Clavel M, Vermorken J.*
Toxic dermatitits induced by 10-ethyl-10-deaza-aminoterapin (10-EdAM), a novel antifolate.
Cancer. 1990 Nov 1;66(9):1910-3.
I.F. = 6,537

358. *Nardi M,* ***Cognetti F****, Pollera CF, Giulia MD, Lombardi A, Atlante G, Calabresi F.*
Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
J Clin Oncol. 1990 Jun;8(6):1036-41.
I.F. = 26,36

359. *Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J,* ***Cognetti F****, Aapro MS.*
Cancer in the elderly: why so badly treated?
Lancet. 1990 Apr 28;335(8696):1020-2.
I.F. : 36,421

360. *Schornagel J, Verweij J, de Mulder P, Wildiers J, Kirkpatrick A,* ***Cognetti F****.*

Acute blindness during treatment of recurrent or metastatic nasopharyngeal carcinoma with doxorubicin and CCNU.
Eur J Cancer. 1990;26(7):857.
I.F. = 7,191

361. *Botti C, Cosimelli M, Frezza F, Nuti M, Cognetti F, Cavaliere R.*
Effective intrarterial infusion chemotherapy for locally recurrent breast cancer with axillary metastatic brachial plexopathia. A case report.
J Exp Clin Cancer Res, 9, 4, 1990.
I.F. = 6,217

362. ***Cognetti F****, Pinnarò P, Ruggeri EM, Carlini P, Perrino A, Impiombato FA, Calabresi F, Chilelli MG, Giannarelli D.*
Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.
J Clin Oncol. 1989 Jul;7(7):829-37.
I.F. = 26,36

363. ***Cognetti F****, Pinnarò P, Carlini P, Ruggeri EM, Ambesi Impiombato F, Del Vecchio MR, Giannarelli D, Perrino A.*
Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer.
Cancer. 1988 Jul 15;62(2):251-61.
I.F. = 6,537

364. *Clavel M,* ***Cognetti F****, Dodion F, Wildiers J, Rosso R, Rossi A, Gignoux B, Van Rymenant M, Cortes-Funes H, Dalesio O, et al.*
Combination chemotherapy with methotrexate, bleomycin and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck.
Cancer. 1987 Sep 15;60(6):1173-7.
I.F. = 6,537

365. ***Cognetti F****, Molinari A, Carlini P, Frassineti GL, Pinnarò P , Marangolo M.*
Alternating regimens in recurrent and metastatic squamous cell carcinoma of the head and neck.
Oncology. 1987;44(5):270-2.
I.F. = 2.262

366. ***Cognetti F****, Pinnarò P, Carlini P, Ruggeri EM.*
High dose cisplatinum in recurrent and metastatic head and neck squamous cell carcinoma.
J Exp Clin Cancer Res 6: 139-142, 1987.
I.F. = 6,217

367. ***Cognetti F****, Clerico M, Vermorken J, Van Rymenant M, Rossi A, Kirkpatrick A, Dalesio O, Clavel M.*
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
Eur J Cancer Clin Oncol. 1986 Jul;22(7):891-2.

I.F. = 7,191

368. *Pinnarò P, Ruggeri EM, Carlini P, Giovannelli M,* ***Cognetti F****.*
Cumulative or delayed nephrotoxicity after cisplatin (DDP) treatment.
Tumori. 1986 Apr 30;72(2):197-200.
I.F. 2016 = 1,233

369. *Dodion P,* ***Cognetti F****, Van Rymenant M, Dalesio O, Kirkpatrick A, Rozencweig M.*
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
Eur J Cancer Clin Oncol. 1986 Mar;22(3):241-3.
I.F. = 7,191

370. ***Cognetti F****, Carlini P, Pinnarò P, Ruggeri EM, Caporali C.*
Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses.
Oncology. 1986;43(5):292-4.
I.F. = 2.262

371. ***Cognetti F****, Pinnarò P, Carlini P, Conti EM, Cortese M , Pollera CF.*
Randomized open cross-over trial between metoclopramide (MCP) and dexamethasone (DMX) for the prevention of cisplatinum-induced nausea and vomiting.
Eur J Cancer Clin Oncol. 1984 Feb;20(2):183-7.
I.F. = 7,191

372. ***Cognetti F****, Pinnarò P, Carlini P, Caporali C, Ruggeri EM, Pollera CF.*
Improved control of cisplatin-induced emesis with a methoclopramide-dexamethasone combination.
Cancer Chemother Pharmacol. 1984;13(3):235-7.
I.F. 2,808

373. *Pollera CF,* ***Cognetti F****, Nardi M, Mazza D.*
Sudden death after acute dystonic reaction to high dose metoclopramide.
Lancet 2: 460-461, 1984.
I.F. : 36,421

374. *Cognetti F, Pinnarò P, Carlini P, Del Vecchio MR, Ambesi Impiombato F, Perrino A, Ruggeri EM, Cortese M.*
Combination chemotherapy (CABO) prior to radiation for locally advanced inoperable squamous cell carinoma of the head and neck.
J Exp Clin Cancer Res 3:271-275, 1984.
I.F. = 6,217

375. *Cognetti F, Pinnarò P, Carlini P, Perrino A, Ruggeri EM, Oria A, Cortese M.*
CABO treatment (cisplatin, methotrexate, bleomycin, vincristine) in advanced or recurrent squamous cell carcinoma of the head and neck.
J Exp Clin Cancer Res. 3: 411-417, 1984.
I.F. = 6,217

376. *Cognetti F, Pinnarò P, Cortese M, Carlini P, Terzoli E, Pollera CF.*
Hypomagnesemia and cisplatinum: an evaluation of 54 patients.
J Exp Clin Cancer Res 1: 139-142, 1982.
I.F. = 6,217

377. *Benedetti Panici P, Di Roberto P, Margariti PA, Villani L, Sacco F,* ***Cognetti F****, BompianiA.*
The treatment of 48 patients affected by ovarian carcinoma at stages III and IV F.I.G.O.
Eur J Gynaecol Oncol. 1981;2(3):89-97.
I.F. 2008 = 0.641

Gli Impact Factor (I.F.) sono riferiti all'anno 2017 salvo dove diversamente indicato

PUBBLICAZIONI SU RIVISTE NON RECENSITE

1) *Sega E, Sega FM,* ***Cognetti F****.*
Considerazioni sull'immunologia ed immunoterapia del carcinoma gastrico.
Il Policlinico 94:693-696, 1977

2) *Terzoli E,* ***Cognetti F****.*
La terapia medica e radiante del carcinoma ovarico.
Rivista di oncologia 1:83-99, 1978

3) *Sega E, Mottolese M, Cordiali Fei P, Di Paola M, Colizza S, Gallo Curcio C, Sega FM,* ***Cognetti F****.*
Caratterizzazione e valutazione immunologica del paziente con cancro del polmone.
Il Policlinico 85:669-695, 1978

4) *Cordiali Fei P, Mottolese M,* ***Cognetti F****, Ricci P, Sedati A, Marziale P, Sega E.*
Immunologic monitoring of surgically treated patients with ovarian cancer.
IRCS Med. Sci. 6:379, 1978

5) ***Cognetti F****, Benedetti Panici P, Di Roberto P, Coppola A, Pollera CF.*
La chemioterapia del carcinoma della cervice uterina.
Recentia Medica 17:297-306, 1978

6) *Benedetti Panici P, Di Roberto P,* ***Cognetti F****, Teramo R.*
Linfomi maligni in gravidanza.
Recentia Medica 17:291-296, 1978

7) ***Cognetti F****, Benedetti Panici P, Di Roberto P, Terzoli E.*
Lo staging nel carcinoma dell'ovaio.
Recentia Medica 17:299-304, 1978

8) ***Cognetti F****, Pollera CF, Barduagni M, Terzoli E, Delle Chiaie S.*
Prevenzione della nefrotossicità indotta da farmaci antiblastici: cis-diammino-cloroplatino e methotrexate ad alte dosi.
Rivista di Oncologia 2:162-167, 1979

9) *Barduagni A, Calabresi F, Delle Chiaie S,* ***Cognetti F****, Pollera CF.*
L'associazione vincristina, adriamicina e CCNU nel trattamento del carcinoma mammario in fase avanzata. Note preliminari.
Chemioterapia Oncologica 4:166-171, 1981

10) *Terzoli E,* ***Cognetti F****, Zampa G, Carlini P, Pinnarò P.*
Methotrexate versus methotrexate + bleomicina nel trattamento del cancro della testa e del collo in fase avanzata.
Giornale Italiano di Oncologia 1:231-234, 1981

11) ***Cognetti F****, Carlini P.*
Proposte per la classificazione del carcinoma esocrino del pancreas.
Il gastroenterologo 6:1-7, 1981

12) *Terzoli E, Zampa G, Pinnarò P, Carlini P, Barduagni M,* ***Cognetti F****, Del Vecchio MR, Ambesi Impiombato F.*
Radiochemioterapia: trattamento adiuvante del carcinoma mammario con linfonodi positivi. Valutazione dei risultati a tre anni.
Giornale Italiano di Oncologia 2:43-48, 1982

13) ***Cognetti F****, Carlini P, Pinnarò P, Terzoli E.*
Considerazioni sul vomito indotto da chemioterapia antineoplastica.
Il gastroenterologo 4:1-11, 1982

14) ***Cognetti F****, Terzoli E, Pinnarò P, Carlini P, Cortese M.*
Medium intravenous doses of metoclopramide for prevention of cisplatin induced nausea and vomiting.
Giornale Italiano di Oncologia 2:201-204, 1982

15) *Pollera CF, Nardi M,* ***Cognetti F****, Milasi G, Mazza D.*
Effetti tossici della chemioterapia antiblastica sull'apparato gastrointestinale. Rassegna critica.
Il gastroenterologo 5:155-163, 1983

16) *Pinnarò P,* ***Cognetti F****, Carlini P, Ruggeri EM.*
Chemioterapia endoarteriosa nei tumori epatici. Revisione critica della letteratura.
Il gastroenterologo 6:125-131, 1984

17) *Terzoli E, Zampa G, Andriani A, Beni A, Carlini P,* ***Cognetti F****, Izzo F, Pinnarò P, Nisticò C.*
ADM + MMC + 5FU (i.v.) vs ADM + MMC + 5FU (os) in patients affected with gastrointestinal tumors in an advanced stage.
Il gastroenterologo 6:132-134, 1984

18) *Pollera CF, Mazza D, Nardi M, Carlini P, Zampa G, Pinnarò P,* ***Cognetti F,*** *Ruggeri EM.*
Il trattamento delle reazioni tossiche locali da agenti antineoplastici.

Annale di Medicina Navale 15:163-178, 1985

19) ***Cognetti F.***
La chemioterapia adiuvante nel carcinoma squamocellulare della testa e del collo in fase localmente avanzata.
Bollettino di Oncologia Testa e Collo pag. 1:8-11, 1989

20) ***Cognetti F.***
L'Europa attivamente impegnata nella ricerca clinica sul trattamento dei tumori della testa e del collo.
Bollettino di Oncologia Testa e Collo 2:5-9, 1989

21) ***Cognetti F****, Scinto AF.*
Riduzione della neutropenia febbrile da chemioterapia: il ruolo del filgrastim.
Hospital Management, marzo 1994

22) *Bianco AR, Tonato M, Clerici M,* ***Cognetti F****, Luporini G, Marangolo M, Marsoni S, Roila F, Ricci C, Salvati F, Torri V.*
Studio clinico controllato sull'efficacia della terapia adiuvante nel carcinoma polmonare non a piccole cellule (Studio ALPI: Adjuvant Lung Project Italy).
La Radiologia Medica Vol.90, suppl.1, n.3, 291-294, 1995

23) ***Cognetti F.***
Legge sui Comitati Etici: quali nuove responsabilità per l'oncologo.
Τεχνη, vol 2, 3:146 1998

24) *D'Alessio A, Fabi A, Papaldo P,* ***Cognetti F.***
Recenti progressi nel trattamento medico del carcinoma della mammella.
Annali Italiani di Medicina Interna, 14 (suppl. 1):109-114, 1999

25) *Amunni G, Bolis G, Cascinu S, Cazzola M, Gamucci T,* ***Cognetti F*** *et al.*
Consensus Meeting. Uso di eritropoietina nei tumori ginecologici.
Forum, 9.3 (suppl. 4), 1999

26) *Bernardo G, Aglietta M, Amadori D, Beccaglia P, Belli G, Bianco R, Cionini L,* ***Cognetti F****, Colucci G, Comela G, Di Costanzo F, Marchetti P, Pronzato P.*
La prevalenza dell'anemia nei pazienti oncologici sottoposti a chemioterapia. Indagine italiana a livello nazionale.
Recenti Progressi in Medicina, 2001

27) ***Cognetti F****, Ceribelli A.*
Nonsmall-cell lung cancer Managment.
Hospital Pharmacy Europe. 2004

28) *Ferretti G, Di Cosimo S, Ceribelli A, Milella M, Gelibter A,* ***Cognetti F.***
Suspected pharmacological interactions in a cancer patient during methadone maintenance.
Addictive disorders & their treatment Vol.3,n.2 June 2004

LIBRI

1) *Santoro A,* ***Cognetti F****.*
Il follow-up del paziente neoplastico.
Collana: "I manuali delle scuole SIOMS e SSOSB" Frati L, Santi L, 1992

2) ***Cognetti F*** *et al*
Basi scientifiche per la definizione di linee guida in ambito clinico per i tumori epiteliali della testa e del collo.
Progetto finalizzato applicazioni cliniche della ricerca oncologica a cura del CNR, 1999

3) ***Cognetti F****, Conte F.*
L'anemia nel paziente oncologico – obiettivi di trattamento e opzioni terapeutiche: presente e futuro.
Passoni Editore, 2003

4) *Cavalli F,* ***Cognetti F****, Costa A, Orecchia R.*
Fondamenti di oncologia clinica.
Elsevier, 2006

5) Venturini M. , ***Cognetti F***, Nappi O., Siani A., Ficarra V., Martorana G., Mirone V., Vespasiani G., De Placido S., Perrone F., Gallucci M., Muto G., Biti G., Cartenì G., Iacobelli S., Pronzato P., Milella M.
Carcinoma Renale e Raccomandazioni di Comportamento Clinico. Opinion Paper del Gruppo Italiano Carcinoma Renal (GIR).
Science & Medicine Publications, 2010.

6) Di Costanzo F. , ***Cognetti F***, Benedetti Panici P.
Manuale pratico di oncologia: fondamenti per il medico non oncologo.
Editeam, 2010.

7) Boldrini M., Smerrieri S., ***Cognetti F.***
Il male "~~in~~"curabile:i progressi nella lotta contro il cancro e il nuovo ruolo della comunicazione.
Intermedia Editore, 2014.

CAPITOLI DI LIBRI

1) ***Cognetti F**, Licitra L.*
Tumori del distretto cervico-facciale.
In: "Terapia medica oncologica" Santoro A, Bonadonna G.
EdiSES, Napoli: pp. 299-319, 1990

2) ***Cognetti F**, Licitra L.*
Tumori del distretto cervico-facciale.
In: "Terapia medica oncologica" Santoro A, Bonadonna G.
EdiSES, Napoli: pp. 257-275, 1992. Seconda Edizione

3) ***Cognetti F**, Scinto AF, Ferraresi V.*
Il trattamento del carcinoma mammario avanzato con alte dosi di chemioterapia e aggiunta di fattori di crescita mielopoietici in G. Robustelli della Cuna
Intensità di dose nel carcinoma mammario, Progressi in Oncologia Clinica
Pavia, Edizioni Medico Scientifiche, 1995

4) *Carlini P, Ruggeri EM, De Marco S, **Cognetti F**.*
Il trattamento conservativo nella laringe: Il parere dell'Oncologo medico.
In: "Terapie integrate per la conservazione d'organo in Oncologia".
Latina, 8 febbraio 1997 pp. 97-100

5) *Carlini P, Ruggeri EM, **Cognetti F**.*
Ruolo della chemioterapia nel trattamento del carcinoma dell'ipofaringe e dell'esofago cervicale. LXXXV Congresso Nazionale della Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, Relazione Ufficiale "I tumori dell'ipofaringe e dell'esofago cervicale"
Roma, 27-30 Maggio 1998, p.201-214.

6) ***Cognetti F*** et al
"L'Oncologo Medico Italiano".
Hyppocrates Edizioni Medico-Scientifiche, 1998

7) ***Cognetti F**, Ruggeri EM, Carlini P, De Marco S.*
Le neoplasie della testa e del collo.
In: "Working Expert Group on guidelines for specific medical treatment in advanced cancer patients" Amadori D, De Conno F, Maltoni M.
UTET 1999 pp. 1-18

8) ***Cognetti F**, De Marco S.*
Il carcinoma epiteliale dell'ovaio.
In: "Working Expert Group on guidelines for specific medical treatment in advanced cancer patients" Amadori D, De Conno F, Maltoni M.
UTET 1999 pp. 44-50

9) ***Cognetti F**, Milella M.*
I carcinomi dell'utero.
In: "Working Expert Group on guidelines for specific medical treatment in advanced cancer patients" Amadori D, De Conno F, Maltoni M.
UTET 1999 pp. 44-50

10) ***Cognetti F**, Milella M.*
Consenso informato ed etica in oncologia.
Atti dell'Accademia Lancisiana, Vol XLIII - n. 1 - 1999

11) *Pollera CF, D'Alessio A, **Cognetti F**.*
Il Carcinoma della Vescica. Terapia medica.
In: "Argomenti di Oncologia" Bumma C, Airoldi M
Archimedica Editori, Torino 1999

12) ***Cognetti F**, Carlini P.*
Carcinoma della mammella.
Neoplasie ormono-dipendenti ed ormono-resistenti.
In: "Manuale di terapia delle malattie endocrine e metaboliche" Andreani D, Tamburano G
Delfino Antonio Editore 2001

13) ***Cognetti F**, Gelibter A.*
Tumori delle vie biliari.
In: "I tumori del tratto gastroenterico" a cura di Zaniboni A, Gennari L, Olmi P.
Ed. Masson, 2003

14) *Carlini P, Salesi N, Priolo C, Saracino B, De Carlini P, Rugger EM, **Cognetti F**.*
Ruolo dell'ormonoterapia adiuvante nel carcinoma della prostata
Educazionale pp. 31-35, 2003

15) *Savarese A, **Cognetti F**.*
Practical Guide on how to deliver chemotherapy.
In: "Chemotherapy for gynecologic neoplasm: current therapy and novel approaches".
Marcel Dekker Inc., New York, pp. 187-200, 2004

16) ***Cognetti F**, Ciccarese M.*
Protocolli chemioterapici e cardiotossicità nelle neoplasie maligne cardiache
In: "Tumori del cuore" Basso C., Valente M.L., Tiene G.
Monografie di Cardiologia (Società Italiana di Cardiologia)
Morgagni Leonardo, Cisalpino, Lancesi, 2005

17) ***Cognetti F**, Felici A.*
I trattamenti medici
In: "Fondamenti di oncologia clinica" Cavalli F, Cognetti F, Costa A, Orecchia R.
Elsevier, 2006

18) ***Cognetti F**.*
Nuove prospettive per un approccio integrato e multidisciplinare
In: "Il carcinoma epatocellulare"
Elsevier, 2008

Il sottoscritto esprime il proprio consenso affinché i dati personali forniti possano essere trattati nel rispetto del Decreto legislativo 30 giugno 2003, n. 196, e ss.mm.ii., per gli adempimenti connessi alla presente procedura

Roma, _____ Francesco Cognetti